EP2414346B1 - Autotaxin inhibitors - Google Patents

Autotaxin inhibitors Download PDF

Info

Publication number
EP2414346B1
EP2414346B1 EP10707839.6A EP10707839A EP2414346B1 EP 2414346 B1 EP2414346 B1 EP 2414346B1 EP 10707839 A EP10707839 A EP 10707839A EP 2414346 B1 EP2414346 B1 EP 2414346B1
Authority
EP
European Patent Office
Prior art keywords
compound
pyridine
carboxylic acid
tetrahydro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP10707839.6A
Other languages
German (de)
French (fr)
Other versions
EP2414346A1 (en
Inventor
Melanie Schultz
Kai Schiemann
Wolfgang Staehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP10707839.6A priority Critical patent/EP2414346B1/en
Publication of EP2414346A1 publication Critical patent/EP2414346A1/en
Application granted granted Critical
Publication of EP2414346B1 publication Critical patent/EP2414346B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
  • ATX Autotaxin
  • LPA lysophosphatidic acid
  • LPC lysophatidylcholine
  • LPA is an intracellular lipid mediator, which influences a multiplicity of biologic and biochemical processes such as smooth muscle contraction, thrombocyte aggregation and apoptosis ( Tigyi et al., Prog. Lipid Res. 2003, 42: 498 ; Mills et al., Nat. Rev. Cancer 2003, 3: 582 ; Lynch et al. Prost. Lipid Med. 2001, 64: 33 ). Furthermore, LPA is found in increased concentrations in plasma and ascites fluid of ovarian cancer patients of early and late phase.
  • LPA has been shown to promote tumor cell proliferation, survival, migration and invasion into neighboring tissues, which can result in the formation of metastases ( Xu et al., Clinical Cancer Research 1995, 1: 1223 ; Xu et al., Biochem. J. 1995, 309 : 933). These biological and pathobiological processes are switched on through the activation of G-protein coupled receptors by LPA ( Contos et al., Mol. Pharm. 2000, 58: 1188 ).
  • LPA is potentially also involved in prostate, breast, melanoma, head and neck, bowel and thyroid cancers.
  • ATX belongs to the family of nucleotide pyrophosphatases and phosphodiesterases ( Goding et al., Immunol. Rev. 1998, 161: 11 ). It represents an important starting point for anti-tumor therapy ( Mills et al. Nat. Rev. Cancer 2003, 3: 582 ; Goto et al. J. Cell. Biochem. 2004, 92: 1115 ), since it is increasingly expressed in tumors and effects tumor cell proliferation and invasion into neighboring tissues both of which can lead to the formation of metastases ( Nam et al. 2000, Oncogene, Vol. 19 Seite 241 ). In addition, in the course of angiogenesis ATX together with other anti-angiogenetic factors brings about blood vessel formation ( Nam et al.
  • Angiogenesis is an important process during tumor growth as it secures supply of the tumor with nutrients. Therefore, the inhibition of angiogenesis is an important starting point of cancer and tumor therapy, by means of which the tumor is to be starved ( Folkman, Nature Reviews Drug Discovery 2007, 6: 273-286 ).
  • ATX is a relatively novel target
  • the amount of preclinical data on protein production, in vitro and in vivo assays is rather limited.
  • No target-dependent cell model has been described but LPA itself is an excellent biomarker to follow ATX inhibition in vitro and in vivo. Neither structural information nor reference compounds are available.
  • the present invention has the object to provide novel autotaxin inhibitors.
  • a compound according to formula (I) and above embodiments is provided, wherein: is independently substituted by a chemical group selected from the group consisting of: and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • the object of the present invention has surprisingly been solved by providing a compound selected from the group consisting of: Compound 1 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
  • Compound 2 2-[3-(4-Chlorophenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
  • Compound 3 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-trifluoromethyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carbox
  • the term "effective amount” refers to any amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • All stereoisomers of the compounds of the invention are contemplated, either in a mixture or in pure or substantially pure form.
  • the compounds of the invention can have asymmetric centers at any of the carbon atoms. Consequently, they can exist in the form of their racemates, in the form of the pure enantiomers and/or diastereomers or in the form of mixtures of these enantiomers and/or diastereomers.
  • the mixtures may have any desired mixing ratio of the stereoisomers.
  • the compounds of the invention which have one or more centers of chirality and which occur as racemates or as diastereomer mixtures can be fractionated by methods known per se into their optical pure isomers, i.e. enantiomers or diastereomers.
  • the separation of the compounds of the invention can take place by column separation on chiral or nonchiral phases or by recrystallization from an optionally optically active solvent or with use of an optically active acid or base or by derivatization with an optically active reagent such as, for example, an optically active alcohol, and subsequent elimination of the radical.
  • the compounds of the invention may be present in the form of their double bond isomers as "pure" E or Z isomers, or in the form of mixtures of these double bond isomers.
  • the compounds of the invention may be in the form of the tautomers, such as keto-enol tautomers.
  • the compounds of the invention can be in the form of any desired prodrugs such as, for example, esters, carbonates, carbamates, ureas, amides or phosphates, in which cases the actually biologically active form is released only through metabolism.
  • Any compound that can be converted in vivo to provide the bioactive agent i.e. compounds of the invention is a prodrug within the scope and spirit of the invention.
  • Any biologically active compound that was converted in vivo by metabolism from any of the compounds of the invention is a metabolite within the scope and spirit of the invention.
  • the compounds of the invention can, if they have a sufficiently basic group such as, for example, a secondary or tertiary amine, be converted with inorganic and organic acids into salts.
  • the pharmaceutically acceptable salts of the compounds of the invention are preferably formed with hydrochloric acid, hydrobromic acid, iodic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, sulfoacetic acid, trifluoroacetic acid, oxalic acid, malonic acid, maleic acid, succinic acid, tartaric acid, racemic acid, malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, taurocholic acid, glutaric acid, stearic acid, glutamic acid or aspartic acid.
  • the salts which are formed are, inter alia, hydrochlorides, chlorided, hydrobromides, bromides, iodides, sulfates, phosphates, methanesulfonates, tosylates, carbonates, bicarbonates, formates, acetates, sulfoacetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, mandelates, fumarates, lactates, citrates, glutarates, stearates, aspartates and glutamates.
  • the stoichiometry of the salts formed from the compounds of the invention may moreover be an integral or non-integral multiple of one.
  • the compounds of the invention can, if they contain a sufficiently acidic group such as, for example, the carboxy, sulfonic acid, phosphoric acid or a phenolic group, be converted with inorganic and organic bases into their physiologically tolerated salts.
  • suitable inorganic bases are ammonium, sodium hydroxide, potassium hydroxide, calcium hydroxide
  • organic bases are ethanolamine, diethanolamine, triethanolamine, ethylenediamine, t-butylamine, t-octylamine, dehydroabietylamine, cyclohexylamine, dibenzylethylene-diamine and lysine.
  • the stoichiometry of the salts formed from the compounds of the invention can moreover be an integral or non-integral multiple of one.
  • the compounds of the invention are in the form of their solvates and, in particular, hydrates which can be obtained for example by crystallization from a solvent or from aqueous solution. It is moreover possible for one, two, three or any number of solvate or water molecules to combine with the compounds of the invention to give solvates and hydrates.
  • solvate is meant a hydrate, an alcoholate, or other solvate of crystallization.
  • polymorphic forms or modifications It is known that chemical substances form solids which exist in different order states which are referred to as polymorphic forms or modifications.
  • the various modifications of a polymorphic substance may differ greatly in their physical properties.
  • the compounds of the invention can exist in various polymorphic forms and certain modifications may moreover be metastable. All these polymorphic forms of the compounds are to be regarded as belonging to the invention.
  • the compounds of the invention are surprisingly characterized by a strong and/or selective inhibition of autotaxin.
  • the compounds of the invention can be advantageously administered at lower doses compared to other less potent or selective inhibitors of the prior art while still achieving equivalent or even superior desired biological effects.
  • a dose reduction may advantageously lead to less or even no medicinal adverse effects.
  • the high inhibition selectivity of the compounds of the invention may translate into a decrease of undesired side effects on its own regardless of the dose applied.
  • the compounds of the invention being autotaxin inhibitors generally have an inhibition constant IC 50 of less than about 30 ⁇ M, and preferably less than about 5 ⁇ M.
  • inhibiting, inhibition and/or retardation are intended to refer for the purposes of the present invention to as follows: "partial or complete inhibiting, inhibition and/or retardation". In this case, it is within the specialist knowledge of the average person skilled in the art to measure and determine such inhibiting, inhibition, and/or retardation by means of the usual methods of measurement and determination. Thus, a partial inhibiting, inhibition and/or retardation, for example, can be measured and determined in relation to a complete inhibiting, inhibition and/or retardation.
  • the object of the present invention has surprisingly been solved in another aspect by providing a process for the preparation of a compound of the invention, comprising the steps:
  • a physiologically acceptable salt of a compound of the invention can also be obtained by isolating and/or treating the compound of the invention obtained by the described reaction with an acid or a base.
  • the compounds of the invention and also the starting materials for their preparation are, are prepared by methods as described in the examples or by methods known per se, as described in the literature (for example in standard works, such as Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart ; Organic Reactions, John Wiley & Sons, Inc., New York ), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.
  • the starting materials for the claimed process may, if desired, also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds of the invention. On the other hand, it is possible to carry out the reaction stepwise.
  • the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under the respective reaction conditions.
  • suitable solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichlorethylene, 1,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides,
  • Polar solvents are in general preferred.
  • suitable polar solvents are chlorinated hydrocarbons, alcohols, glycol ethers, nitriles, amides and sulfoxides or mixtures thereof. More preferred are amides, especially dimethylformamide (DMF).
  • the reaction temperature is between about -100° C and 300° C, depending on the reaction step and the conditions used.
  • Reaction times are generally in the range between some minutes and several days, depending on the reactivity of the respective compounds and the respective reaction conditions. Suitable reaction times are readily determinable by methods known in the art, for example reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally lie in the range between 10 min and 48 hrs.
  • a base of a compound of the invention can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in a preferably inert solvent, such as ethanol, followed by evaporation.
  • Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts.
  • inorganic acids for example sulfuric acid, sulfurous acid, dithionic acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as, for example, orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, hexadecanoic acid, octadecanoic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid,
  • inorganic acids for
  • Salts with physiologically unacceptable acids for example picrates, can be used to isolate and/or purify the compounds of the invention.
  • compounds of the invention can be converted into the corresponding metal salts, in particular alkali metal salts or alkaline earth metal salts, or into the corresponding ammonium salts, using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate).
  • bases for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate.
  • Suitable salts are furthermore substituted ammonium salts, for example the dimethyl-, diethyl- and diisopropylammonium salts, monoethanol-, diethanol- and diisopropanolammonium salts, cyclohexyl- and dicyclohexylammonium salts, dibenzylethylenediammonium salts, furthermore, for example, salts with arginine or lysine.
  • the free bases of the compounds of the invention can be liberated from their salts by treatment with strong bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate, so long as no further acidic groups are present in the molecule.
  • strong bases such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate
  • salt formation can likewise be achieved by treatment with bases.
  • bases are alkali metal hydroxides, alkaline earth metal hydroxides or organic bases in the form of primary, secondary or tertiary amines.
  • Every reaction step described herein can optionally be followed by one or more working up procedures and/or isolating procedures.
  • Suitable such procedures are known in the art, for example from standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).
  • Examples for such procedures include, but are not limited to evaporating a solvent, distilling, crystallization, fractionised crystallization, extraction procedures, washing procedures, digesting procedures, filtration procedures, chromatography, chromatography by HPLC and drying procedures, especially drying procedures in vacuo and/or elevated temperature.
  • the object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention.
  • the object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin.
  • a corresponding use for the preparation of a medicament for the treatment and/or prophylaxis of the aforementioned conditions is intended to be comprised.
  • the object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions selected from the group consisting of: "cancer, tumour, malignant tumours, benign tumours, solid tumours, sarcomas, carcinomas, hyperproliferative disorders, carcinoids, Ewing sarcomas, Kaposi sarcomas, brain tumours, tumours originating from the brain and/or the nervous system and/or the meninges, gliomas, glioblastomas, neuroblastomas, stomach cancer, kidney cancer, kidney cell carcinomas, prostate cancer, prostate carcinomas, connective tissue tumours, soft tissue sarcomas, pancreas tumours, liver tumours, head tumours, neck tumours, laryngeal cancer, oesophageal cancer, thyroid cancer, osteosarcomas, retinoblastomas, thymoma
  • Compounds of the invention may be used in combination with one or more other active substances (ingredients, drugs) in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of the invention or the other substances have utility.
  • the combination of the drugs is safer or more effective than either drug alone, or the combination is safer or more effective than would it be expected based on the additive properties of the individual drugs.
  • Such other drug(s) may be administered, by a route and in an amount commonly used contemporaneously or sequentially with a compound of the invention.
  • a combination product containing such other drug(s) and the compound of the invention is preferred.
  • combination therapy also includes therapies in which the compound of the invention and one or more other drugs are administered on different overlapping schedules. It is contemplated that when used in combination with other active ingredients, the compound of the present invention or the other active ingredient or both may be used effectively in lower doses than when each is used alone. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the invention.
  • Examples of other active substances that may be administered in combination with a compound of the invention, and either administered separately or in the same pharmaceutical composition, include, but are not limited to the compounds classes and specific compounds listed in Table 1: Table 1 Alkylating agents Cyclophosphamide Lomustine Busulfane Procarbazine Ifosfamide Altretamine Melphalane Estramustinphosphate Hexamethylmelamine Mechlorethamine Thiotepa Streptozocine Chlorambucil Temozolomide dacarbazine Semustine Carmustine Platinum agents Cisplatin Carboplatin Oxaliplatin ZD-0473 (AnorMED) Spiroplatin Lobaplatin (AeternaZentaris) Carboxyphthalatoplatinum Satraplatin (Johnson Matthey) Tetraplatin Ormiplatin BBR-3464 (Hoffrnann-La Roche) Iproplatin SM-11355 (Sumitomo) AP-5280 (Access) Antimetabol
  • a compound of the invention is administered in combination with one or more known anti-tumor agents, such as the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxics, antiproliferative agents, prenyl proteintransferase inhibitors, HMG-CoA-reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, angiogenesis inhibitors.
  • one or more known anti-tumor agents such as the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxics, antiproliferative agents, prenyl proteintransferase inhibitors, HMG-CoA-reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, angiogenesis inhibitors.
  • the compounds of the invention are in particular well suited for administration in combination with radiotherapy.
  • the synergistic effects of VEGF inhibition in combination with radiotherapy are known to the skilled artisan ( WO 00/61186 ).
  • estrogen receptor modulators in the course of the present invention refers to compounds that interfere with or inhibit the binding of estrogen to estrogen receptor - independently from the mode of action.
  • Non-limiting examples of estrogen receptor modulators are tamoxifen, raloxifen, idoxifen, LY353381, LY 117081, toremifen, fulvestrant, 4-[7-(2,2-Dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl-2,2-dimethyl-propanoate, 4,4'-Dihydroxybenzophenon-2,4-dinitrophenylhydrazone and SH646.
  • androgen receptor modulators in the course of the present invention refers to compounds that interfere with or inhibit the binding of androgens to androgen receptor - independently from the mode of action.
  • Non-limiting examples of androgen receptor modulators are finasteride and other 5alpha-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abirateron acetate.
  • retinoid receptor modulators in the course of the present invention refers to compounds that interfere with or inhibit the binding of retinoids to retinoid receptor - independently from the mode of action.
  • Non-limiting examples of retinoid receptor modulators are bexaroten, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, alpha-difluoromethylornithine, ILX23-7553, trans-N-(4'-Hydroxyphenyl)retinamide and N-4-carboxyphenylretinamide.
  • cytotoxics in the course of the present invention refers to compounds that primarily trigger cell death through direct action on cell function(s) or which interfere with or inhibit cell myosis, such as alkylating agents, tumor necrosis factors, intercalating agents, microtubule inhibitors and topoisomerase inhibitors.
  • Non-limiting examples of cytotoxics are tirapazimin, sertenef, cachectine, ifosfamide, tasonermine, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcit, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustin, improsulfan-tosylate, trofosfamide, nimustine, dibrospidium-chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-amindichloro(2-methylpyridine)platin, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)-bis-mu-(hexane-1,6-diamine)-
  • Non-limiting examples of microtubule inhibitors are paclitaxel, vindesine-sulfate, 3',4'-dideshydro-4'-desoxy-8'-norvincaleukoblastine, docetaxol, rhizoxine, dolastatine, mivobuline-isethionate, auristatine, cemadotine, RPR109881, BMS184476, vinflunine, cryptophycine, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)-benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.
  • topoisomerase inhibitors are topotecane, hycaptamine, irinotecane, rubitecane, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusine, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo-[de]-pyrano-[3',4':b,7]indolizino[1,2b]quiinoline-10,13(9H,15H)-dione, lurtotecane, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecine, BNP1350, BNPI1100, BN80915, BN80942,
  • Non-limiting examples of antiproliferative agents are antisense RNA- and antisense-DNA oligonucleotides, such as G3139, ODN698, RVASKRAS, GEM231 and INX3001, as well as antimetabolites scuh as enocitabine, carmofur, tegafur, pentostatine, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabin-ocfosfate, fosteabine sodiumhydrate, raltitrexed, paltitrexide, emitefur, tiazofurine, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-desoxy-2'-methylidencytidine, 2'-fluoromethylen-2'-desoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4
  • Antiproliferative agents also comprises monoclonal antibodies against growth factors that have not been listed under “angiogenesis inhibitors”, such as trastuzumab, as well as tumor suppressor genes, such as p53.
  • a medicament according to above aspects and embodiments is provided, wherein in such medicament comprises at least one additional pharmacologically active substance (drug, ingredient).
  • the at least one pharmacologically active substance is a substance as described herein.
  • a medicament according to above aspects and embodiments is provided, wherein the medicament is applied before and/or during and/or after treatment with at least one additional pharmacologically active substance.
  • the at least one pharmacologically active substance is a substance as described herein.
  • composition comprising a therapeutically effective amount of at least one compound of the invention.
  • the pharmaceutical composition contains at least one additional compound selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, diluents, carriers and/or additional pharmaceutically active substance other than the compounds of the invention.
  • a pharmaceutical composition which comprises at least one compound of the invention, at least one pharmacologically active substance other than the compounds of the invention as described herein; and a pharmaceutically acceptable carrier.
  • a further embodiment of the present invention is a process for the manufacture of said pharmaceutical compositions, characterized in that one or more compounds according to the invention and one or more compounds selected from the group consisting of solid, liquid or semiliquid excipients, auxiliaries, adjuvants, diluents, carriers and pharmaceutically active agents other than the compounds according to the invention, are converted in a suitable dosage form.
  • kits comprising a therapeutically effective amount of at least one compound of the invention and/or at least one pharmaceutical composition as described herein and a therapeutically effective amount of at least one further pharmacologically active substance other than the compounds of the invention.
  • compositions of the present invention may be administered by any means that achieve their intended purpose.
  • administration may be by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal, transocular, subcutaneous, intraperitoneal, transdermal, or buccal routes.
  • administration may be by the oral route.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. Parenteral administration is preferred. Oral administration is especially preferred.
  • Suitable dosage forms include, but are not limited to capsules, tablets, pellets, dragees, semi-solids, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, which can be produced according to methods known in the art, for example as described below:
  • non-chemical routes for the production of pharmaceutical compositions and/or pharmaceutical preparations comprise processing steps on suitable mechanical means known in the art that transfer one or more compounds of the invenion into a dosage form suitable for administration to a patient in need of such a treatment.
  • the transfer of one or more compounds of the invention into such a dosage form comprises the addition of one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds of the invention.
  • Suitable processing steps include, but are not limited to combining, milling, mixing, granulating, dissolving, dispersing, homogenizing, casting and/or compressing the respective active and non-active ingredients.
  • active ingredients are preferably at least one compound of the invention and one or more additional compounds other than the compounds of the invention, which show valuable pharmaceutical properties, preferably those pharmaceutical active agents other than the compounds of the invention, which are disclosed herein.
  • Particularly suitable for oral use are tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal use are suppositories, suitable for parenteral use are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical use are ointments, creams or powders.
  • the compounds of the invention may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations.
  • the preparations indicated may be sterilised and/or comprise assistants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
  • assistants such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
  • Suitable excipients are organic or inorganic substances, which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the compounds of the invention, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose, sucrose, mannitol, sorbitol or starch (maize starch, wheat starch, rice starch, potato starch), cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, magnesium stearate, talc, gelatine, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, polyvinyl pyrrolidone and/or vaseline.
  • enteral for example oral
  • parenteral or topical administration do not react with the compounds of the invention
  • carbohydrates such as lactose, sucrose, mannitol
  • disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries include, without limitation, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable coatings, which, if desired, are resistant to gastric juices.
  • concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • the tablet, dragee or pill can comprise an inner dosage and an outer dosage component me latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, acetyl alcohol, solutions of suitable cellulose preparations such as acetyl-cellulose phthalate, cellulose acetate or hydroxypropylmethyl-cellulose phthalate, are used.
  • Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly.
  • tablets, coated tablets, capsules, syrups, suspensions, drops or suppositories are used for enteral administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application.
  • the compounds of the invention can also be lyophilized and the lyophilizates obtained can be used, for example, for the production of injection preparations.
  • the preparations indicated can be sterilized and/or can contain excipients such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colorants, flavourings and/or aromatizers. They can, if desired, also contain one or more further active compounds, e.g. one or more vitamins.
  • Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatine, as well as soft, sealed capsules made of gelatine and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
  • suitable liquids such as fatty oils, or liquid paraffin.
  • stabilizers may be added.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatine.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions.
  • suspensions of the active compounds as appropriate oily injection suspensions may be administered.
  • Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400).
  • Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran, optionally, the suspension may also contain stabilizers.
  • inhalation sprays for administration as an inhalation spray, it is possible to use sprays in which the active ingredient is either dissolved or suspended in a propellant gas or propellant gas mixture (for example CO 2 or chlorofluorocarbons).
  • a propellant gas or propellant gas mixture for example CO 2 or chlorofluorocarbons.
  • the active ingredient is advantageously used here in micronized form, in which case one or more additional physiologically acceptable solvents may be present, for example ethanol.
  • Inhalation solutions can be administered with the aid of conventional inhalers.
  • Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
  • gelatine rectal capsules which consist of a combination of the active compounds with a base.
  • Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
  • the compounds of the present invention will be in the form of pharmaceutically acceptable salts.
  • Other salts may, however, be useful in the preparation of the compounds of the invention or of their pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic bases, e.g. quaternary ammonium salts.
  • the pharmaceutical preparations can be employed as medicaments in human and veterinary medicine.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function. Said therapeutic effective amount of one or more of the compounds of the invention is known to the skilled artisan or can be easily determined by standard methods known in the art.
  • suitable doses that are therapeutically effective lie in the range between 0.0005 mg and 1000 mg, preferably between 0.005 mg and 500 mg and especially between 0.5 mg and 100 mg per dose unit.
  • the daily dose is preferably between about 0.001 mg/kg and 10 mg/kg of body weight.
  • dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Some of the specific compounds are more potent than others. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means. A preferred means is to measure the physiological potency of a given compound.
  • mammalian species are regarded as being comprised.
  • such mammals are selected from the group consisting of "primate, human, rodent, equine, bovine, canine, feline, domestic animals, cattle, livestock, pets, cow, sheep, pig, goat, horse, pony, donkey, hinny, mule, hare, rabbit, cat, dog, guinea pig, hamster, rat, mouse". More preferably, such mammals are humans. Animal models are of interest for experimental investigations, providing a model for treatment of human diseases.
  • the specific dose for the individual patient depends, however, on the multitude of factors, for example on the efficacy of the specific compounds employed, on the age, body weight, general state of health, the sex, the kind of diet, on the time and route of administration, on the excretion rate, the kind of administration and the dosage form to be administered, the pharmaceutical combination and severity of the particular disorder to which the therapy relates.
  • the specific therapeutic effective dose for the individual patient can readily be determined by routine experimentation, for example by the doctor or physician, which advises or attends the therapeutic treatment.
  • the susceptibility of a particular cell to treatment with the subject compounds may be determined by in vitro testing.
  • a culture of the cell is combined with a subject compound at varying concentrations for a period of time sufficient to allow the active agents to show a relevant reaction, usually between about one hour and one week.
  • cultured cells from a biopsy sample may be used.
  • 5 can be prepared by using an alloc-protected starting material instead of the BOC-protected one:
  • the final products can be prepared without the use of any protecting group:
  • pyridon-(4) (starting material 10, 1 g, 10.1 mmol) was dissolved in 50 ml abs. ethanol. Then starting material 11 (1.4 g, 10.1 mmol) and sulfur (0.3 g, 10.1 mmol) were added. 2 ml diethyl amine (20.2 mmol) were added dropwise to the yellow suspension (over 20 Min) resulting in a brown solution. The reaction was stirred at room temperature over night. Another ml of Diethyl amine (10.1 mmol) was added and the reaction was stirred for another 7 h. The reaction was concentrated in vacuo. Thereby the desired product 12 was isolated as a viscous brown matter (3.2 g, 75% content of 12 , 95% yield), which could be used without further purification.
  • the desired product 40 was isolated quantitatively (2.6 g, 6.4 mmol) and further used without purification.
  • Autotaxin activity is measured indirectly by means of Amplex Red Reagent.
  • Amplex Red is measured as fluorogenic indicator for generated H 2 O 2 .
  • Autotaxin converts substrate lysophosphatidylcholine (LPC) to phosphocholine and lysophosphatidylic acid (LPA). After the conversion phosphocholine is reacted with alkaline phosphatase to obtain inorganic phosphate and choline. During the next step choline is oxidized with choline oxidase to yield betaine, whereby H 2 O 2 is generated.
  • LPC substrate lysophosphatidylcholine
  • LPA lysophosphatidylic acid
  • H 2 O 2 reacts with Amplex Red Reagent in the presence of peroxidase (Horseradish peroxidase) in an 1:1 stochiometry and yields highly fluorescent resorufin.
  • the generated fluorescence is measured in a reaction-dependent kinetic mode in order to enable subtraction of fluorescence signals of possible other fluorescent compounds that are not part of the reaction from total measured fluorescence.
  • LPC L-a-lysophosphatidyl-choline
  • the reaction is started through the addition of 5 ⁇ l L-a-lysophosphatidyl-choline (LPC), whereby the final concentration of LPC is 75 ⁇ M.
  • LPC L-a-lysophosphatidyl-choline
  • the mixture is incubated for 90 min. at 37°C.
  • Amplex Red Reagent peroxidase (Horseradish peroxidase) and choline oxidase are added.
  • the fluorescence is immediately measured at a wavelength of 612 nm with an excitation wavelength of 485 nm in a "Tecan Ultra multimode" fluorescence reader.
  • the activity of autotaxin is indirectly calculated via the amount of detected generated H 2 O 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Description

    Technical field
  • The present invention relates to compounds as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
    • Prior art
  • Autotaxin (ATX) is the enzyme apparently responsible for increased lysophosphatidic acid (LPA) levels in ascites and plasma of ovarian cancer patients (Xu et al., Clinical Cancer Research 1995, 1: 1223; Xu et al., Biochem. J. 1995, 309: 933), because it transforms lysophatidylcholine (LPC) to LPA (Tokumura et al., J. Biol. Chem. 2002, 277: 39436; Umezu-Gozo et al., J. Biol. Chem. 2002, 158: 227).
  • LPA is an intracellular lipid mediator, which influences a multiplicity of biologic and biochemical processes such as smooth muscle contraction, thrombocyte aggregation and apoptosis (Tigyi et al., Prog. Lipid Res. 2003, 42: 498; Mills et al., Nat. Rev. Cancer 2003, 3: 582; Lynch et al. Prost. Lipid Med. 2001, 64: 33). Furthermore, LPA is found in increased concentrations in plasma and ascites fluid of ovarian cancer patients of early and late phase.
  • LPA has been shown to promote tumor cell proliferation, survival, migration and invasion into neighboring tissues, which can result in the formation of metastases (Xu et al., Clinical Cancer Research 1995, 1: 1223; Xu et al., Biochem. J. 1995, 309: 933). These biological and pathobiological processes are switched on through the activation of G-protein coupled receptors by LPA (Contos et al., Mol. Pharm. 2000, 58: 1188).
  • Increased levels of LPA, altered receptor expression and altered responses to LPA may contribute to the initiation, progression or outcome of ovarian cancer. Furthermore, LPA is potentially also involved in prostate, breast, melanoma, head and neck, bowel and thyroid cancers.
  • For all these reasons in the course of treating tumor patients it is desirable to lower the LPA level. This can be achieved through the inhibition of enzymes which are involved in LPA biosynthesis, such as ATX (Sano et al., J. Biol. Chem. 2002, 277: 21197; Aoki et al., J. Biol. Chem. 2003, 277: 48737).
  • ATX belongs to the family of nucleotide pyrophosphatases and phosphodiesterases (Goding et al., Immunol. Rev. 1998, 161: 11). It represents an important starting point for anti-tumor therapy (Mills et al. Nat. Rev. Cancer 2003, 3: 582; Goto et al. J. Cell. Biochem. 2004, 92: 1115), since it is increasingly expressed in tumors and effects tumor cell proliferation and invasion into neighboring tissues both of which can lead to the formation of metastases (Nam et al. 2000, Oncogene, Vol. 19 Seite 241). In addition, in the course of angiogenesis ATX together with other anti-angiogenetic factors brings about blood vessel formation (Nam et al. Cancer Res. 2001, 61: 6938). Angiogenesis is an important process during tumor growth as it secures supply of the tumor with nutrients. Therefore, the inhibition of angiogenesis is an important starting point of cancer and tumor therapy, by means of which the tumor is to be starved (Folkman, Nature Reviews Drug Discovery 2007, 6: 273-286).
  • Mutagenesis studies suggest an essential function of the PDE domain of ATX for LPA generation. Though this particular PDE domain shares little homology with other known PDEs, it is considered to be druggable by NCEs.
  • No severe adverse effects are expected for the inhibition of ATX as LPA involved in wound healing in this context is produced by another pathway.
  • Since ATX is a relatively novel target, the amount of preclinical data on protein production, in vitro and in vivo assays is rather limited. No target-dependent cell model has been described but LPA itself is an excellent biomarker to follow ATX inhibition in vitro and in vivo. Neither structural information nor reference compounds are available.
  • Compounds that are capable of inhibiting ATX are described in Peng et al. (Bioorganic & Medicinal Chemistry Letters 2007,17: 1634-1640). The there described compounds represent lipid analogues, which structurally share no similarities with the compounds of the present invention.
  • Further prior art documents are as follows:
    • DE 19834751 relates to heterobicyclic substituted (hetero)aromatic amidines or nitriles as thrombin inhibitors, antithrombotic agents or intermediates. The patent application does not mention the inhibition of autotaxin.
    • WO 99/24035 discloses benzothiazolecarboxamides as protein tyrosine kinase inhibitors. The patent application does not mention the inhibition of autotaxin.
    • WO 2002/102380 describes monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors. The patent application does not mention the inhibition of autotaxin.
    • WO 2003/097615 is directed to treatment of fibroproliferative diseases, such as diabetic neuropathy, involving identifying a non-peptide small molecule, selectively binding to a transforming growth factor beta kinase receptor and administering the molecule to subjects. The patent application does not mention the inhibition of autotaxin.
    • US 2003/0139431 relates to the use of quinazoline- and quinolino-guanidine derivatives for treating urge incontinence, pain, memory disorders, endocrine disorders, psychotic behaviour, diabetes, hypertension and gastrointestinal disorders. The patent application does not mention the inhibition of autotaxin.
    • WO 2004/099192 describes heterocycle substituted carboxylic acids which can be used in the treatment of metabolic disorders. The patent application does not mention the inhibition of autotaxin.
    • WO 2005/003100 deals with the use of quinazoline derivatives for the treatment of tubulin inhibitor mediated diseases, such as cancer, autoimmune diseases, autoimmune lymphoproliferative syndrome, inflammation and viral infections. The patent application does not mention the inhibition of autotaxin.
    • WO 2005/023761 is directed to cytokine inhibitors that are useful for treating rheumatoid arthritis and ulcerative colitis. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/062972 discloses heterocyclic compounds that function as selective inhibitors of serine protease enzymes of the coagulation cascade and can be used for the treatment of arterial cardiovascular thromboembolic disorders, thromboembolic disorders, unstable angina and acute coronary syndrome. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/066879 relates to benzo-heterocyclic compounds as voltage-gated potassium channel modulators. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/072828 is directed to heteroaromatic quinoline compounds that serve as PDE inhibitors, in particular PDE10 inhibitors. These compounds can be used for the treatment of central nervous system disorders, such as psychotic disorders, anxiety disorders, movement disorders, mood disorders and neurodegenerative disorders. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/074147 describes 4-arylamino-quinazoline as caspase-3 cascade activators that can be used for the treatment of cancer, autoimmune diseases, autoimmune lymphoproliferative syndrome, synovial cell hyperplasia, inflammation and viral infections. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/099379 discloses benzoimidazole, benzooxazole and benzothiazole derivatives as betasecretase inhibitors. The patent application does not mention the inhibition of autotaxin.
    • WO 2006/108107 deals with diarylamine derivatives that are steroid hormone nuclear receptor modulators and can be used for the treatment of hypokalemia, hypertension, congestive heart failure, renal failure, artherosclerosis and obesity. The patent application does not mention the inhibition of autotaxin.
    • WO 2007/030582 relates to alkyl amine acompounds as potassium channel 1 function inhibitors that are useful for the treatment of arrhythmia, atrial fibrillation, atrial flutter, supraventricular arrhythmias, gastrointestinal disorders, esophagitis and asthma. The patent application does not mention the inhibition of autotaxin.
    • WO 2007/076034 describes fused bicyclic arene compounds that function as hepatitis C virus replication inhibitors and can be used for the treatment hepatitis C or other viral infections. The patent application does not mention the inhibition of autotaxin.
    • WO 2007/110868 discloses novel heterocyclic compounds that exhibit a dopamine receptor, preferably D4 receptor, antagonistic activity and/or a PDE5 inhibitory activity. These compounds can be used for the treatment of descreased libido, orgasm disorder and erectile dysfunction. The patent application does not mention the inhibition of autotaxin.
    • WO 2008/038051 is directed to heterocyclic compounds for the treatment of inflammatory or immunological diseases, such as cystic fibrosis. The patent application does not mention the inhibition of autotaxin.
    • WO 2008/038053 deals with heterocyclic compounds as voltage-dependent potassium channel inhibitors. The patent application does not mention the inhibition of autotaxin.
    • WO 2008/060621 is directed to aminopyrrolidines as chemokine receptor antagonists. The patent application does not mention the inhibition of autotaxin.
    • WO 2008/091580 relates to fungicidal amides and methods for controlling plant diseases caused by a fungal pathogen. The patent application does not mention the inhibition of autotaxin.
    • WO 2008/014286 A1 discloses organic alkenyl- or alkinyl-substituted phosphonates and their use as LPA receptor antagonists. The compounds disclosed therein are structurally different to the compounds of the present invention.
  • The citation of any reference in this application is not an admission that the reference is relevant prior art to this application.
    • Description of the invention
  • The present invention has the object to provide novel autotaxin inhibitors.
  • The object of the present invention has surprisingly been solved in one aspect by providing a compound according to formula (I)
    Figure imgb0001
     wherein:
    • W1, W2
    together independently form "-N=N-, -C(O)-O-,
    Y1
    is independently selected from the group consisting of "-C(O)-, - C(S)-, -N(R10)-C(O)-, -C(O)-N(R11)-, -C(R12)(R13)-, single bond";
    Y2
    is independently selected from the group consisting of "-C(R14)(R15)-, -O-, -N(R16)-, -C(O)-NH-, single bond";
    Z1
    is independently selected from the group consisting of "O, S, N(R17)";
    L
    is independently selected from the group consisting of the group consisting of:
    Figure imgb0002
    Figure imgb0003
    Figure imgb0004
    Figure imgb0005
    B
    is independently selected from the group consisting of " aryl", wherein "aryl, " can be independently substituted with one or more identical or different substituents selected from the group consisting of: "(i) "hydrogen, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halogen, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, - NHX1, -NX2X3, -NO2, -OH, -OCF3, -SCF3, -SH, -O-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-X4, -C(O)O-X5, -C(O)NH-X6, -C(O)NX7X8, -O-X9, -O(-X10-O)a-H (a = 1, 2, 3, 4, 5), -O(-X11-O)b-X12 (b = 1, 2, 3, 4, 5), - OC(O)-X13, -OC(O)-O-X14, -OC(O)-NHX15, -O-C(O)-NX16X17, -OP(O)(OX18)(OX19), -OSi(X20)(X21)(X22), -OS(O2)-X23, - NHC(O)-NH2, -NHC(O)-X24, -NX25C(O)-X26, -NH-C(O)-O-X27, -NH-C(O)-NH-X28, -NH-C(O)-NX29X30, -NX31-C(O)-O-X32, - NX33-C(O)-NH-X34, -NX35-C(O)-NX36X37, -NHS(O2)-X38, - NX39S(O2)-X40, -S-X41, -S(O)-X42, -S(O2)-X43, -S(O2)NH-X44, -S(O2)NX45X46, -S(O2)O-X47, -P(O)(OX48)(OX49), - Si(X50)(X51)(X52), -C(NH)-NH2, -C(NX53)-NH2, -C(NH)-NHX54, -C(NH)-NX55X56, -C(NX57)-NHX58, -C(NX59)-NX60X61, -NH-C(O)-NH-O-X62, -NH-C(O)-NX63-O-X64, -NX65-C(O)-NX66-O-X67, -N(-C(O)-NH-O-X68)2, -N(-C(O)-NX69-O-X70)2, -N(-C(O)-NH-O-X71)(-C(O)-NX72-O-X73), -C(S)-X74, -C(S)-O-X75, -C(S)-NH-X76, -C(S)-NX77X78, -C(O)-NH-O-X79, -C(O)-NX80-O-X81, -C(S)-NH-O-X82, -C(S)-NX83-O-X84, -C(O)-NH-NH-X85, -C(O)-NH-NX86X87, -C(O)-NX88-NX89X90, - C(S)-NH-NH-X91, -C(S)-NH-NX92X93, -C(S)-NX94-NX95X96, - C(O)-C(O)-O-X97, -C(O)-C(O)-NH2, -C(O)-C(O)-NHX98, -C(O)-C(O)-NX99X100, -C(S)-C(O)-O-X101, -C(O)-C(S)-O-X102, - C(S)-C(S)-O-X103, -C(S)-C(O)-NH2, -C(S)-C(O)-NHX104, - C(S)-C(O)-NX105X106, -C(S)-C(S)-NH2, -C(S)-C(S)-NHX107, - C(S)-C(S)-NX108X109, -C(O)-C(S)-NH2, -C(O)-C(S)-NHX110, - C(O)-C(S)-NX111X112";
    wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102, X103, X104, X105, X106, X107, X108, X109, X110, X111, X112 are independently from each other selected from the group consisting of: "alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and
    wherein alternatively X7, X8 and/or X16, X17 and/or X29, X30 and/or X36, X37 and/or X45, X46 and/or X55, X56 and/or X60, X61 and/or X77, X78 and/or X86, X87 and/or X89, X90 and/or X92, X93 and/or X95, X96 and/or X99, X100 and/or X105, X106 and/or X108, X109 and/or X111, X112 respectively together can also form "heterocyclyl";
    wherein optionally above substituents of substituents group (i) can in turn independently from each other be substituted with one or more identical or different substituents V;
    R1, R2, R3, R4, R10, R11, R12, R13, R14, R15, R16,R17
    are independently from each other selected from the group consisting of: "V";
    V
    is independently selected from the group consisting of: "(i) "hydrogen, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halogen, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, - NHA1, -NA2A3, -NO2, -OH, -OCF3, -SCF3, -SH, -O-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-A4, -C(O)O-A5, -C(O)NH-A6, -C(O)NA7A8, -O-A9, -O(-A10-O)a-H (a = 1, 2, 3, 4, 5), -O(-A11-O)b-A12 (b = 1, 2, 3, 4, 5), - OC(O)-A13, -OC(O)-O-A14, -OC(O)-NHA15, -O-C(O)-NA16A17, -OP(O)(OA18)(OA19), -OSi(A20)(A21)(A22), -OS(O2)-A23, - NHC(O)-NH2, -NHC(O)-A24, -NA25C(O)-A26, -NH-C(O)-O-A27, -NH-C(O)-NH-A28, -NH-C(O)-NA29A30, -NA31-C(O)-O-A32, - NA33-C(O)-NH-A34, -NA35-C(O)-NA36A37, -NHS(O2)-A38, - NA39S(O2)-A40, -S-A41, -S(O)-A42, -S(O2)-A43, -S(O2)NH-A44, -S(O2)NA45A46, -S(O2)O-A47, -P(O)(OA48)(OA49), - Si(A50)(A51)(A52), -C(NH)-NH2, -C(NA53)-NH2, -C(NH)-NHA54, -C(NH)-NA55A56, -C(NA57)-NHA58, -C(NA59)-NA60A61, -NH-C(O)-NH-O-A62, -NH-C(O)-NA63-O-A64, -NA65-C(O)-NA66-O-A67, -N(-C(O)-NH-O-A68)2, -N(-C(O)-NA69-O-A70)2, -N(-C(O)-NH-O-A71)(-C(O)-NA72-O-A73), -C(S)-A74, -C(S)-O-A75, -C(S)-NH-A76, -C(S)-NA77A78, -C(O)-NH-O-A79, -C(O)-NA80-O-A81, -C(S)-NH-O-A82, -C(S)-NA83-O-A84, -C(O)-NH-NH-A85, -C(O)-NH-NA86A87, -C(O)-NA88-NA89A90, - C(S)-NH-NH-A91, -C(S)-NH-NA92A93, -C(S)-NA94-NA95A96, - C(O)-C(O)-O-A97, -C(O)-C(O)-NH2, -C(O)-C(O)-NHA98, -C(O)-C(O)-NA99A100, -C(S)-C(O)-O-A101, -C(O)-C(S)-O-A102, - C(S)-C(S)-O-A103, -C(S)-C(O)-NH2, -C(S)-C(O)-NHA104, - C(S)-C(O)-NA105A106, -C(S)-C(S)-NH2, -C(S)-C(S)-NHA107, - C(S)-C(S)-NA108A109, -C(O)-C(S)-NH2, -C(O)-C(S)-NHA110, - C(O)-C(S)-NA111A112";
    wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104, A105, A106, A107, A108, A109, A110, A111, A112 are independently from each other selected from the group consisting of: "alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively A7, A8 and/or A16, A17 and/or A29, A30 and/or A36, A37 and/or A45, A46 and/or A55, A56 and/or A60, A61 and/or A77, A78 and/or A86, A87 and/or A89, A90 and/or A92, A93 and/or46 A95, A96 and/or A99, A100 and/or A105, A106 and/or A108, A109 and/or A111, A112 respectively together can also form "heterocyclyl";
    wherein optionally above substituents of substituents group (i) can in turn independently from each other be substituted with one or more identical or different substituents V;
    n
    is independently 0, 1, 2, 3 or 4;
    and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • In a preferred embodiment, a compound according to formula (I) and above embodiments is provided, wherein:
    Figure imgb0006
     is independently substituted by a chemical group selected from the group consisting of:
    Figure imgb0007
    Figure imgb0008
    Figure imgb0009
     and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • In a preferred embodiment, a compound according to formula (I) and above embodiments is provided, wherein:
    • W1, W2
    together independently form "-N=N-, -C(O)-O-";
    Y1
    is independently selected from the group consisting of "-C(O)-,-N(R10)-C(O)-, -C(O)-N(R11)-, -OC(O)-, single bond";
    Z1
    is independently "O";
    B
    is independently selected from the group consisting of "4-chloro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethylsulfanyl-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro-4-trifluoromethoxy-phenyl, 3,5-bis-trifluoromethyl-phenyl, 4-isopropylphenyl, 4-tert.butyl-phenyl, 3,5-dichloro-phenyl, 4-chloro-2-fluoro-phenyl, 3-chloro-phenyl, 2-fluoro-5-trifluoromethyl-phenyl, 3-chloro-4-trifluoromethyl-phenyl, 3,4-dichloro-phenyl, 2,5-dichlorophenyl, 2-methoxy-phenyl, 4-methoxy-phenyl, 4-nitro-phenyl, 4-bromo-phenyl, 5-chloro-2-methoxy-phenyl, 4-fluoro-phenyl, 3-bromo-4-fluoro-phenyl, 6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl";
    R1, R2, R3, R4, R10, R11, R12, R13, R14, R15
    are independently from each other selected from the group consisting of: "hydrogen, alkyl, methyl, isopropyl, tert.butyl, halogen, -F, -Br, -Cl, -CN, -CF3, -SF3, -OF3, -O-alkyl, -O-methyl, -NO2, -S(O)2-methyl"
    V
    is independently selected from the group consisting of "hydrogen, alkyl, methyl, isopropyl, tert.butyl, halogen, -F, -Br, -Cl, -CN, -CF3, -SF3, -OH, -O-alkyl, -O-methyl, -NO2, -S(O)2-methyl";
    n
    is independently 0, 1 or 2;
    and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  • In another aspect, the object of the present invention has surprisingly been solved by providing a compound selected from the group consisting of:
    Compound 1
    Figure imgb0010
         		6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 2
    Figure imgb0011
         		2-[3-(4-Chlorophenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 3
    Figure imgb0012
         		6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-trifluoromethyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 4
    Figure imgb0013
         		6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-isopropyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 5
    Figure imgb0014
         		6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-propionylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid
    Compound 6
    Figure imgb0015
         		amide 2-[3-(4-Chlorophenyl)-propionylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 7
    Figure imgb0016
         		2-[3-(4-Isopropylphenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 8
    Figure imgb0017
         		2-[3-(3,5-Dichlorophenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 9
    Figure imgb0018
         		6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluorophenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 10
    Figure imgb0019
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 11
    Figure imgb0020
         		6-(1H-Benzotriazole-5-carbonyl)-2-[2-(3-chloro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 12
    Figure imgb0021
         		6-(1 H-Benzotriazole-5-carbonyl)-2-[3-(3,5-dichloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 13
    Figure imgb0022
         		2-[2-(3-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 14
    Figure imgb0023
         		2-[2-(4-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 15
    Figure imgb0024
         		6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-2-fluoro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 16
    Figure imgb0025
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-3-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 17
    Figure imgb0026
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 18
    Figure imgb0027
         		2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 19
    Figure imgb0028
         		2-[3-(4-Chloro-phenyl)-ureido]-6-(pyridine-3-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 20
    Figure imgb0029
         		2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 21
    Figure imgb0030
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 22
    Figure imgb0031
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-3-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 23
    Figure imgb0032
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-4-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 24
    Figure imgb0033
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(3-pyridin-2-yl-propionyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
    Compound 25
    Figure imgb0034
         		6-(1H-Benzotriazole-5-carbonyl)-2-(3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester
    Compound 26
    Figure imgb0035
         		2-[3-(4-Chloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester
    Compound 27
    Figure imgb0036
         		1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea
    Compound 28
    Figure imgb0037
         		2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide]
    Compound 29
    Figure imgb0038
         		2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide
    Compound 30
    Figure imgb0039
         		2-[3-(4-Trifluoromethyl-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide
    Compound 31
    Figure imgb0040
         		2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide
    Compound 32
    Figure imgb0041
         		2-[3-(4-Trifluoromethylphenyl)-ureido]-benzothiazole-6-carboxylic acid (1H-benzotriazol-5-yl)-amide
    Compound 33
    Figure imgb0042
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3,5-dichloro-benzylamide
    Compound 34
    Figure imgb0043
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-benzylamide
    Compound 35
    Figure imgb0044
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-propyl]-amide
    Compound 36
    Figure imgb0045
         		6-(1 H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide
    Compound 37
    Figure imgb0046
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide
    Compound 38
    Figure imgb0047
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2,5-dichloro-benzylamide
    Compound 39
    Figure imgb0048
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide
    Compound 40
    Figure imgb0049
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-1-hydroxymethyl-ethyl]-amide
    Compound 41
    Figure imgb0050
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-methoxy-benzylamide
    Compound 42
    Figure imgb0051
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide
    Compound 43
    Figure imgb0052
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-nitro-phenyl)-ethyl]-amide
    Compound 44
    Figure imgb0053
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide
    Compound 45
    Figure imgb0054
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 5-chloro-2-methoxy-benzylamide
    Compound 46
    Figure imgb0055
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-2-fluoro-benzylamide
    Compound 47
    Figure imgb0056
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide
    Compound 48
    Figure imgb0057
         		[2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester
    Compound 49
    Figure imgb0058
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethylsulfanyl -benzylamide
    Compound 50
    Figure imgb0059
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethyl-benzyl ester
    Compound 51
    Figure imgb0060
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3-bromo-4-fluoro-benzylamide
    Compound 52
    Figure imgb0061
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-dichloro-benzyl ester
    Compound 53
    Figure imgb0062
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzyl ester
    Compound 54
    Figure imgb0063
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethyl-benzyl ester
    Compound 55
    Figure imgb0064
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-trifluoromethyl-benzyl ester
    Compound 56
    Figure imgb0065
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethylsulfanyl -benzyl ester
    Compound 57
    Figure imgb0066
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethoxybenzyl ester
    Compound 58
    Figure imgb0067
         		3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethoxybenzyl ester
    Compound 59
    Figure imgb0068
         		(1H-Benzotriazol-5-yl)-{3-[3-(4-methoxy-phenyl)-piperidine-1-carbonyl]-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl}-methanone
    Compound 60
    Figure imgb0069
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethoxy-benzylamide
    Compound 61
    Figure imgb0070
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide
    Compound 62
    Figure imgb0071
         		6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amide
    Compound 63
    Figure imgb0072
         		3-{[6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carbonyl]-amino}-3-(4-tert-butyl-phenyl)-propionic acid methyl ester
  • For the avoidance of doubt, if chemical name and chemical structure of the above illustrated compounds do not correspond by mistake, the chemical structure is regarded to unambigously define the compound.
  • All the above generically or explicitly disclosed compounds, including preferred subsets/embodiments of the herein disclosed formula (I) and Compounds 1 to 63, are hereinafter referred to as compounds of the (present) invention.
  • The nomenclature as used herein for defining compounds, especially the compounds according to the invention, is in general based on the rules of the IUPAC organisation for chemical compounds and especially organic compounds.
  • The terms indicated for explanation of the above compounds of the invention always, unless indicated otherwise in the description or in the claims, have the following meanings:
    • The term "unsubstituted" means that the corresponding radical, group or moiety has no substituents.
    • The term "substituted" means that the corresponding radical, group or moiety has one or more substituents. Where a radical has a plurality of substituents, and a selection of various substituents is specified, the substituents are selected independently of one another and do not need to be identical.
    • The terms "alkyl" or "A" as well as other groups having the prefix "alk" for the purposes of this invention refer to acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight-chain and preferably have 1 to 8 carbon atoms, i.e. C1-C8-alkanyls, C2-C8-alkenyls and C2-C8-alkynyls. Alkenyls have at least one C-C double bond and alkynyls at least one C-C triple bond. Alkynyls may additionally also have at least one C-C double bond. Examples of suitable alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, 2- or 3-methyl-pentyl, n-hexyl, 2-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-icosanyl, n-docosanyl, ethylenyl (vinyl), propenyl (-CH2CH=CH2; -CH=CH-CH3, -C(=CH2)-CH3), butenyl, pentenyl, hexenyl, heptenyl, octenyl, octadienyl, octadecenyl, octadec-9-enyl, icosenyl, icos-11-enyl, (Z)-icos-11-enyl, docosnyl, docos-13-enyl, (Z)-docos-13-enyl, ethynyl, propynyl (-CH2-C≡CH, - C≡C-CH3), butynyl, pentynyl, hexynyl, heptynyl, octynyl. Especially preferred is C1-4-alkyl. A C1-4-alkyl radical is for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl.
    • The term "(C9-C30)alkyl" for the purposes of this invention refers to acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight-chain and have 9 to 30 carbon atoms, i.e. C9-30-alkanyls, C9-30-alkenyls and C9-30-alkynyls. C9-30-Alkenyls have at least one C-C double bond and C9-30-alkynyls at least one C-C triple bond. C9-30-Alkynyls may additionally also have at least one C-C double bond. Examples of suitable (C9-C30)alkyl radicals are tetradecyl, hexadecyl, octadecyl, eicosanyl, cis-13-docosenyl (erucyl), trans-13-docosenyl (brassidyl), cis-15-tetracosenyl (nervonyl) and trans-15-tetracosenyl.
    • The term "cycloalkyl" for the purposes of this invention refers to saturated and partially unsaturated non-aromatic cyclic hydrocarbon groups/radicals, having 1 to 3 rings, that contain 3 to 20, preferably 3 to 12, most preferably 3 to 8 carbon atoms. The cycloalkyl radical may also be part of a bi- or polycyclic system, where, for example, the cycloalkyl radical is fused to an aryl, heteroaryl or heterocyclyl radical as defined herein by any possible and desired ring member(s). The bonding to the compounds of the general formula can be effected via any possible ring member of the cycloalkyl radical. Examples of suitable cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl and cyclooctadienyl. Especially preferred are C3-C9-cycloalkyl and C4-C8-cycloalkyl. A C4-C8-cycloalkyl radical is for example a cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.
    • The term "heterocyclyl" for the purposes of this invention refers to a mono- or polycyclic system of 3 to 20, preferably 5 or 6 to 14 ring atoms comprising carbon atoms and 1, 2, 3, 4, or 5 heteroatoms, in particular nitrogen, oxygen and/or sulfur which are identical or different. The cyclic system may be saturated, mono- or polyunsaturated but may not be aromatic. In the case of a cyclic system consisting of at least two rings the rings may be fused or spiro- or otherwise connected. Such "heterocyclyl" radicals can be linked via any ring member. The term "heterocyclyl" also includes systems in which the heterocycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the heterocycle is fused to an "aryl", "cycloalkyl", "heteroaryl" or "heterocyclyl" group as defined herein via any desired and possible ring member of the heterocycyl radical. The bonding to the compounds of the general formula can be effected via any possible ring member of the heterocycyl radical. Examples of suitable "heterocyclyl" radicals are pyrrolidinyl, thiapyrrolidinyl, piperidinyl, piperazinyl, oxapiperazinyl, oxapiperidinyl, oxadiazolyl, tetrahydrofuryl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, morpholinyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, imidazolidinyl, 2-aza-bicyclo[2.2.2]octanyl.
    • The term "aryl" for the purposes of this invention refers to a mono- or polycyclic aromatic hydrocarbon systems having 3 to 14, preferably 5 to 14, more preferably 6 to 10 carbon atoms. The term "aryl" also includes systems in which the aromatic cycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the aromatic cycle is fused to an "aryl", "cycloalkyl", "heteroaryl" or "heterocyclyl" group as defined herein via any desired and possible ring member of the aryl radical. The bonding to the compounds of the general formula can be effected via any possible ring member of the aryl radical. Examples of suitable "aryl" radicals are phenyl, biphenyl, naphthyl, 1-naphthyl, 2-naphthyl and anthracenyl, but likewise indanyl, indenyl, or 1,2,3,4-tetrahydronaphthyl. The most preferred aryl is phenyl.
    • The term "heteroaryl" for the purposes of this invention refers to a 3 to 15, preferably 5 to 14, more preferably 5-, 6- or 7-membered mono- or polycyclic aromatic hydrocarbon radical which comprises at least 1, where appropriate also 2, 3, 4 or 5 heteroatoms, preferably nitrogen, oxygen and/or sulfur, where the heteroatoms are identical or different. The number of nitrogen atoms is preferably 0, 1, 2, or 3, and that of the oxygen and sulfur atoms is independently 0 or 1. The term "heteroaryl" also includes systems in which the aromatic cycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the aromatic cycle is fused to an "aryl", "cycloalkyl", "heteroaryl" or "heterocyclyl" group as defined herein via any desired and possible ring member of the heteroaryl radical. The bonding to the compounds of the general formula can be effected via any possible ring member of the heteroaryl radical. Examples of suitable "heteroaryl" are acridinyl, benzdioxinyl, benzimidazolyl, benzisoxazolyl, benzodioxolyl, benzofuranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, carbazolyl, cinnolinyl, dibenzofuranyl, dihydrobenzothienyl, furanyl, furazanyl, furyl, imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl, isobenzylfuranyl, isoindolyl, isoquinolinyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolinyl, quinolyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, thiophenyl, triazinyl, triazolyl.
    • For the purposes of the present invention, the terms "alkyl-cycloalkyl", "cycloalkylalkyl", "alkyl-heterocyclyl", "heterocyclylalkyl", "alkyl-aryl", "arylalkyl", "alkyl-heteroaryl" and "heteroarylalkyl" mean that alkyl, cycloalkyl, heterocycl, aryl and heteroaryl are each as defined above, and the cycloalkyl, heterocyclyl, aryl and heteroaryl radical is bonded to the compounds of the general formula via an alkyl radical, preferably C1-C8-alkyl radical, more preferably C1-C4-alkyl radical.
    • The term "alkyloxy" or "alkoxy" for the purposes of this invention refers to an alkyl radical according to above definition that is attached to an oxygen atom. The attachment to the compounds of the general formula is via the oxygen atom. Examples are methoxy, ethoxy and n-propyloxy, propoxy, isopropoxy. Preferred is "C1-C4-alkyloxy" having the indicated number of carbon atoms.
    • The term "cycloalkyloxy" or "cycloalkoxy" for the purposes of this invention refers to a cycloalkyl radical according to above definition that is attached to an oxygen atom. The attachment to the compounds of the general formula is via the oxygen atom. Examples are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy. Preferred is "C3-C9cycloalkyloxy" having the indicated number of carbon atoms.
    • The term "heterocyclyloxy" for the purposes of this invention refers to a heterocyclyl radical according to above definition that is attached to an oxygen atom. The attachment to the compounds of the general formulae is via the oxygen atom. Examples are pyrrolidinyloxy, thiapyrrolidinyloxy, piperidinyloxy, piperazinyloxy.
    • The term "aryloxy" for the purposes of this invention refers to an aryl radical according to above definition that is attached to an oxygen atom. The attachment to the compounds of the general formula is via the oxygen atom. Examples are phenyloxy, 2-naphthyloxy, 1-naphthyloxy, biphenyloxy, indanyloxy. Preferred is phenyloxy.
    • The term "heteroaryloxy" for the purposes of this invention refers to a heteroaryl radical according to above definition that is attached to an oxygen atom. The attachment to the compounds of the general formula is via the oxygen atom. Examples are pyrrolyloxy, thienyloxy, furyloxy, imidazolyloxy, thiazolyloxy.
    • The term "carbonyl" or "carbonyl moiety" for the purposes of this invention refers to a -C(O)- group.
    • The term "alkylcarbonyl" for the purposes of this invention refers to a "alkyl-C(O)-" group, wherein alkyl is as defined herein.
    • The term "alkoxycarbonyl" or "alkyloxycarbonyl" for the purposes of this invention refers to a "alkyl-O-C(O)-" group, wherein alkyl is as defined herein.
    • The term "alkoxyalkyl" for the purposes of this invention refers to a "alkyl-O-alkyl-" group, wherein alkyl is as defined herein.
    • The term "haloalkyl" for the purposes of this invention refers to an alkyl group as defined herein comprising at least one carbon atom substituent with at least one halogen as defined herein.
    • The term "halogen", "halogen atom", "halogen substituent" or "Hal" for the purposes of this invention refers to one or, where appropriate, a plurality of fluorine (F, fluoro), bromine (Br, bromo), chlorine (Cl, chloro), or iodine (I, iodo) atoms. The designations "dihalogen", "trihalogen" and "perhalogen" refer respectively to two, three and four substituents, where each substituent can be selected independently from the group consisting of fluorine, chlorine, bromine and iodine. "Halogen" preferably means a fluorine, chlorine or bromine atom. Fluorine is most preferred, when the halogens are substituted on an alkyl (haloalkyl) or alkoxy group (e.g. CF3 and CF3O).
    • The term "hydroxyl" or "hydroxy" means an OH group.
    • The term "composition", as in pharmaceutical composition, for the purposes of this invention is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
    • The terms "administration of" and "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individualist need.
  • As used herein, the term "effective amount" refers to any amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
  • All stereoisomers of the compounds of the invention are contemplated, either in a mixture or in pure or substantially pure form. The compounds of the invention can have asymmetric centers at any of the carbon atoms. Consequently, they can exist in the form of their racemates, in the form of the pure enantiomers and/or diastereomers or in the form of mixtures of these enantiomers and/or diastereomers. The mixtures may have any desired mixing ratio of the stereoisomers.
  • Thus, for example, the compounds of the invention which have one or more centers of chirality and which occur as racemates or as diastereomer mixtures can be fractionated by methods known per se into their optical pure isomers, i.e. enantiomers or diastereomers. The separation of the compounds of the invention can take place by column separation on chiral or nonchiral phases or by recrystallization from an optionally optically active solvent or with use of an optically active acid or base or by derivatization with an optically active reagent such as, for example, an optically active alcohol, and subsequent elimination of the radical.
  • The compounds of the invention may be present in the form of their double bond isomers as "pure" E or Z isomers, or in the form of mixtures of these double bond isomers.
  • Where possible, the compounds of the invention may be in the form of the tautomers, such as keto-enol tautomers.
  • It is likewise possible for the compounds of the invention to be in the form of any desired prodrugs such as, for example, esters, carbonates, carbamates, ureas, amides or phosphates, in which cases the actually biologically active form is released only through metabolism. Any compound that can be converted in vivo to provide the bioactive agent (i.e. compounds of the invention) is a prodrug within the scope and spirit of the invention.
  • Various forms of prodrugs are well known in the art and are described for instance in:
    1. (i) Wermuth CG et al., Chapter 31: 671-696, The Practice of Medicinal Chemistry, Academic Press 1996;
    2. (ii) Bundgaard H, Design of Prodrugs, Elsevier 1985; and
    3. (iii) Bundgaard H, Chapter 5: 131-191, A Textbook of Drug Design and Development, Harwood Academic Publishers 1991.
  • Said references are incorporated herein by reference.
  • It is further known that chemical substances are converted in the body into metabolites which may where appropriate likewise elicit the desired biological effect - in some circumstances even in more pronounced form.
  • Any biologically active compound that was converted in vivo by metabolism from any of the compounds of the invention is a metabolite within the scope and spirit of the invention.
  • The compounds of the invention can, if they have a sufficiently basic group such as, for example, a secondary or tertiary amine, be converted with inorganic and organic acids into salts. The pharmaceutically acceptable salts of the compounds of the invention are preferably formed with hydrochloric acid, hydrobromic acid, iodic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, sulfoacetic acid, trifluoroacetic acid, oxalic acid, malonic acid, maleic acid, succinic acid, tartaric acid, racemic acid, malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, taurocholic acid, glutaric acid, stearic acid, glutamic acid or aspartic acid. The salts which are formed are, inter alia, hydrochlorides, chlorided, hydrobromides, bromides, iodides, sulfates, phosphates, methanesulfonates, tosylates, carbonates, bicarbonates, formates, acetates, sulfoacetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, mandelates, fumarates, lactates, citrates, glutarates, stearates, aspartates and glutamates. The stoichiometry of the salts formed from the compounds of the invention may moreover be an integral or non-integral multiple of one.
  • The compounds of the invention can, if they contain a sufficiently acidic group such as, for example, the carboxy, sulfonic acid, phosphoric acid or a phenolic group, be converted with inorganic and organic bases into their physiologically tolerated salts. Examples of suitable inorganic bases are ammonium, sodium hydroxide, potassium hydroxide, calcium hydroxide, and of organic bases are ethanolamine, diethanolamine, triethanolamine, ethylenediamine, t-butylamine, t-octylamine, dehydroabietylamine, cyclohexylamine, dibenzylethylene-diamine and lysine. The stoichiometry of the salts formed from the compounds of the invention can moreover be an integral or non-integral multiple of one.
  • It is likewise possible for the compounds of the invention to be in the form of their solvates and, in particular, hydrates which can be obtained for example by crystallization from a solvent or from aqueous solution. It is moreover possible for one, two, three or any number of solvate or water molecules to combine with the compounds of the invention to give solvates and hydrates.
  • By the term "solvate" is meant a hydrate, an alcoholate, or other solvate of crystallization.
  • It is known that chemical substances form solids which exist in different order states which are referred to as polymorphic forms or modifications. The various modifications of a polymorphic substance may differ greatly in their physical properties. The compounds of the invention can exist in various polymorphic forms and certain modifications may moreover be metastable. All these polymorphic forms of the compounds are to be regarded as belonging to the invention.
  • The compounds of the invention are surprisingly characterized by a strong and/or selective inhibition of autotaxin.
  • Due to their surprisingly strong and/or selective enzyme inhibition, the compounds of the invention can be advantageously administered at lower doses compared to other less potent or selective inhibitors of the prior art while still achieving equivalent or even superior desired biological effects. In addition, such a dose reduction may advantageously lead to less or even no medicinal adverse effects. Further, the high inhibition selectivity of the compounds of the invention may translate into a decrease of undesired side effects on its own regardless of the dose applied.
  • The compounds of the invention being autotaxin inhibitors generally have an inhibition constant IC50 of less than about 30 µM, and preferably less than about 5 µM.
  • The terms "inhibiting, inhibition and/or retardation" are intended to refer for the purposes of the present invention to as follows: "partial or complete inhibiting, inhibition and/or retardation". In this case, it is within the specialist knowledge of the average person skilled in the art to measure and determine such inhibiting, inhibition, and/or retardation by means of the usual methods of measurement and determination. Thus, a partial inhibiting, inhibition and/or retardation, for example, can be measured and determined in relation to a complete inhibiting, inhibition and/or retardation.
  • The object of the present invention has surprisingly been solved in another aspect by providing a process for the preparation of a compound of the invention, comprising the steps:
    • (a) reacting a compound of the formula (II),
      Figure imgb0073
       wherein W1, W2, R1, R2 have the meanings as indicated hereinwith, with a compound of the formula (III)
      Figure imgb0074
       wherein L is selected from the group consisting of:
      Figure imgb0075
      Figure imgb0076
      Figure imgb0077
      Figure imgb0078
       and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated hereinwith, to yield a compound according to formula (I) as indicated hereinwith, in which Y1 denotes "-C(O)-";
      or
    • (b) reacting a compound of the formula (II)
      Figure imgb0079
       wherein W1, W2, R1, R2 have the meanings as indicated hereinwith, with a compound L selected from the group consisting of:
      Figure imgb0080
      Figure imgb0081
       to yield a compound of the formula (IIa)
      Figure imgb0082
       wherein W1, W2, R1, R2 have the meanings as indicated hereinwith; further reacting the compound of formula (IIa) with a compound of formula (IV)
      Figure imgb0083
       wherein R3, R4, B, n have the meanings as indicated hereinwith, to yield a compound according to formula (I) as indicated hereinwith, in which Z1 denotes "O" and Y2 denotes "-N(R16)-" and R16 denotes "H";
      or
    • (c) reacting a compound of the formula (Va) or (Vb)
      Figure imgb0084
       wherein m and n independently are 0, 1 or 2, with a compound of the formula (III)
      Figure imgb0085
       wherein L is selected from the group consisting of:
      Figure imgb0086
      Figure imgb0087
      Figure imgb0088
      Figure imgb0089
       and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claims 1 and 2, in which Y1 denotes "-C(R12)(R13)- and R12, R13 both denote "H" or Y1 denotes "-C(O)-",
      or
    • (c) reacting a compound of the formula (VI)

              HO(O)C-L     (VI)

      wherein L is selected from the group consisting of:
      Figure imgb0090
      Figure imgb0091
       with a compound of the formula (VII)
      Figure imgb0092
       wherein W1, W2, R1, R2 have the meanings as indicated hereinwith; to yield a compound of the formula (VIII)
      Figure imgb0093
       wherein W1, W2, R1, R2 have the meanings as indicated hereinwith; further reacting the compound of formula (VIII) with a compound of formula (IV)
      Figure imgb0094
       wherein R3, R4, B, n have the meanings as indicated hereinwith, to yield a compound according to formula (I) as indicated hereinwith, in which Y1 denotes "-N(R10)-C(O)-", R10 denotes "H", Z1 denotes "O", Y2 denotes "-N(R16)-" and R16 denotes "H";
      or
    • (e) reacting a compound of the formula (IX)
      Figure imgb0095
    wherein L is selected from the group consisting of:
    Figure imgb0096
    Figure imgb0097
     and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated hereinwith, with a compound of the formula (VII)
    Figure imgb0098
     wherein W1, W2, R1, R2 have the meanings as indicated hereinwith; to yield a compound according to formula (I) as indicated hereinwith, in which Y1 denotes "-N(R10)-C(O)-" and R10 denotes "H".
    or
    • (f) reacting a compound of the formula (X)
      Figure imgb0099
    wherein W1, W1, R1, R2, Y1 have the meanings as indicated hereinwith, wherein L is selected from the group consisting of:
    Figure imgb0100
     with a compound of formula (XI)
    Figure imgb0101
     wherein R3, R4, B, n have the meanings as indicated hereinwith, to yield a compound according to formula (I) as indicated hereinwith, in which Z1 denotes "O", Y2 denotes "-N(R16)-" and R16 denotes "H".
  • All crude products were subjected to standard chromatography using solvent mixtures containing methanol, ethanol, isopropanol, n-hexane, cyclohexane or petrol ether, respectively.
  • For a further detailed description of the manufacturing processes, please refer also to the examples and the following general description of the preferred conditions.
  • A physiologically acceptable salt of a compound of the invention can also be obtained by isolating and/or treating the compound of the invention obtained by the described reaction with an acid or a base.
  • The compounds of the invention and also the starting materials for their preparation are, are prepared by methods as described in the examples or by methods known per se, as described in the literature (for example in standard works, such as Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc., New York), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.
  • The starting materials for the claimed process may, if desired, also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds of the invention. On the other hand, it is possible to carry out the reaction stepwise.
  • Preferably, the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under the respective reaction conditions. Examples of suitable solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichlorethylene, 1,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, dimethylformamide (DMF) or N-methyl pyrrolidinone (NMP); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents or mixtures with water. Polar solvents are in general preferred. Examples for suitable polar solvents are chlorinated hydrocarbons, alcohols, glycol ethers, nitriles, amides and sulfoxides or mixtures thereof. More preferred are amides, especially dimethylformamide (DMF).
  • As stated above, the reaction temperature is between about -100° C and 300° C, depending on the reaction step and the conditions used.
  • Reaction times are generally in the range between some minutes and several days, depending on the reactivity of the respective compounds and the respective reaction conditions. Suitable reaction times are readily determinable by methods known in the art, for example reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally lie in the range between 10 min and 48 hrs.
  • A base of a compound of the invention can be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and the acid in a preferably inert solvent, such as ethanol, followed by evaporation. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, sulfurous acid, dithionic acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as, for example, orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, hexadecanoic acid, octadecanoic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, trimethoxybenzoic acid, adamantanecarboxylic acid, p-toluenesulfonic acid, glycolic acid, embonic acid, chlorophenoxyacetic acid, aspartic acid, glutamic acid, proline, glyoxylic acid, palmitic acid, parachlorophenoxyisobutyric acid, cyclohexanecarboxylic acid, glucose 1-phosphate, naphthalenemono- and -disulfonic acids or laurylsulfuric acid.
  • Salts with physiologically unacceptable acids, for example picrates, can be used to isolate and/or purify the compounds of the invention.
  • On the other hand, compounds of the invention can be converted into the corresponding metal salts, in particular alkali metal salts or alkaline earth metal salts, or into the corresponding ammonium salts, using bases (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate). Suitable salts are furthermore substituted ammonium salts, for example the dimethyl-, diethyl- and diisopropylammonium salts, monoethanol-, diethanol- and diisopropanolammonium salts, cyclohexyl- and dicyclohexylammonium salts, dibenzylethylenediammonium salts, furthermore, for example, salts with arginine or lysine.
  • If desired, the free bases of the compounds of the invention can be liberated from their salts by treatment with strong bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate, so long as no further acidic groups are present in the molecule. In the cases where the compounds of the invention have free acid groups, salt formation can likewise be achieved by treatment with bases. Suitable bases are alkali metal hydroxides, alkaline earth metal hydroxides or organic bases in the form of primary, secondary or tertiary amines.
  • Every reaction step described herein can optionally be followed by one or more working up procedures and/or isolating procedures. Suitable such procedures are known in the art, for example from standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart). Examples for such procedures include, but are not limited to evaporating a solvent, distilling, crystallization, fractionised crystallization, extraction procedures, washing procedures, digesting procedures, filtration procedures, chromatography, chromatography by HPLC and drying procedures, especially drying procedures in vacuo and/or elevated temperature.
  • The object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention.
  • The object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin. A corresponding use for the preparation of a medicament for the treatment and/or prophylaxis of the aforementioned conditions is intended to be comprised.
  • The object of the present invention has surprisingly been solved in another aspect by providing a medicament comprising at least one compound of the invention for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions selected from the group consisting of: "cancer, tumour, malignant tumours, benign tumours, solid tumours, sarcomas, carcinomas, hyperproliferative disorders, carcinoids, Ewing sarcomas, Kaposi sarcomas, brain tumours, tumours originating from the brain and/or the nervous system and/or the meninges, gliomas, glioblastomas, neuroblastomas, stomach cancer, kidney cancer, kidney cell carcinomas, prostate cancer, prostate carcinomas, connective tissue tumours, soft tissue sarcomas, pancreas tumours, liver tumours, head tumours, neck tumours, laryngeal cancer, oesophageal cancer, thyroid cancer, osteosarcomas, retinoblastomas, thymoma, testicular cancer, lung cancer, lung adenocarcinoma, small cell lung carcinoma, bronchial carcinomas, breast cancer, mamma carcinomas, intestinal cancer, colorectal tumours, colon carcinomas, rectum carcinomas, gynaecological tumours, ovary tumours/ovarian tumours, uterine cancer, cervical cancer, cervix carcinomas, cancer of body of uterus, corpus carcinomas, endometrial carcinomas, urinary bladder cancer, urogenital tract cancer, bladder cancer, skin cancer, epithelial tumours, squamous epithelial carcinoma, basaliomas, spinaliomas, melanomas, intraocular melanomas, leukaemias, monocyte leukaemia, chronic leukaemias, chronic myelotic leukaemia, chronic lymphatic leukemia, acute leukaemias, acute myelotic leukaemia, acute lymphatic leukemia, lymphomas, angiogenesis, arteriosclerosis, opthalmic diseases, choroidal neovascularization, diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing and/or transplant rejection". A corresponding use for the preparation of a medicament for the treatment and/or prophylaxis of the aforementioned conditions is intended to be comprised.
  • Compounds of the invention may be used in combination with one or more other active substances (ingredients, drugs) in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of the invention or the other substances have utility. Typically the combination of the drugs is safer or more effective than either drug alone, or the combination is safer or more effective than would it be expected based on the additive properties of the individual drugs. Such other drug(s) may be administered, by a route and in an amount commonly used contemporaneously or sequentially with a compound of the invention. When a compound of the invention is used contemporaneously with one or more other drugs, a combination product containing such other drug(s) and the compound of the invention is preferred. However, combination therapy also includes therapies in which the compound of the invention and one or more other drugs are administered on different overlapping schedules. It is contemplated that when used in combination with other active ingredients, the compound of the present invention or the other active ingredient or both may be used effectively in lower doses than when each is used alone. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the invention.
  • Examples of other active substances (ingredients, drugs) that may be administered in combination with a compound of the invention, and either administered separately or in the same pharmaceutical composition, include, but are not limited to the compounds classes and specific compounds listed in Table 1:
    Table 1
    Alkylating agents Cyclophosphamide Lomustine
    Busulfane Procarbazine
    Ifosfamide Altretamine
    Melphalane Estramustinphosphate
    Hexamethylmelamine Mechlorethamine
    Thiotepa Streptozocine
    Chlorambucil Temozolomide
    Dacarbazine Semustine
    Carmustine
    Platinum agents Cisplatin Carboplatin
    Oxaliplatin ZD-0473 (AnorMED)
    Spiroplatin Lobaplatin (AeternaZentaris)
    Carboxyphthalatoplatinum Satraplatin (Johnson Matthey)
    Tetraplatin
    Ormiplatin BBR-3464 (Hoffrnann-La Roche)
    Iproplatin
    SM-11355 (Sumitomo)
    AP-5280 (Access)
    Antimetabolites Azacytidine Tomudex
    Gemcitabine Trimetrexate
    Capecitabine Deoxycoformycine
    5-Fluoruracil Fludarabine
    Floxuridine Pentostatine
    2-Chlordesoxyadenosine Raltitrexede
    6-Mercaptopurine Hydroxyurea
    6-Thioguanine Decitabine (SuperGen)
    Cytarabine Clofarabine (Bioenvision)
    2-Fluordesoxycytidine Irofulven (MGI Pharma)
    Methotrexate DMDC (Hoffmann-La Roche)
    Idatrexate Ethinylcytidine (Taiho)
    Topoisomerase inhibitors Amsacrine Rubitecane (SuperGen)
    Epirubicine Exatecanmesylate (Daiichi)
    Etoposide Quinamed (ChemGenex)
    Teniposide or Mitoxantrone Gimatecane (Sigma- Tau)
    Irinotecane (CPT-11) Diflomotecane (Beaufour-Ipsen)
    7-Ethyl-10-hyd roxyca mptothecine
    TAS-103 (Taiho)
    Topotecane Elsamitrucine (Spectrum)
    Dexrazoxanet (TopoTarget) J-107088 (Merck & Co)
    Pixantrone (Novuspharrna) BNP-1350 (BioNumerik)
    Rebeccamycin-Analogue CKD-602 (Chong Kun Dang)
    (Exelixis) KW-2170 (Kyowa Hakko)
    BBR-3576 (Novuspharrna)
    Antitumor antibiotics Dactinomycin (Actinomycin D) Amonafide
    Azonafide
    Doxorubicin (Adriamycin) Anthrapyrazole
    Deoxyrubicin Oxantrazole
    Valrubicin Losoxantrone
    Daunorubicin (Daunomycin) Bleomycinsulfate (Blenoxan)
    Epirubicin Bleomycinacid
    Therarubicin Bleomycin A
    Idarubicin Bleomycin B
    Rubidazone Mitomycin C
    Plicamycinp MEN-10755 (Menarini)
    Porfiromycin GPX-100 (Gem Pharmaceuticals)
    Cyanomorpholinodoxorubicin
    Mitoxantron (Novantron)
    Antimitotic agents Paclitaxel SB 408075 (GlaxoSmithKline)
    Docetaxel
    Colchicin E7010 (Abbott)
    Vinblastine PG-TXL (Cell Therapeutics)
    Vincristine IDN 5109 (Bayer)
    Vinorelbine A 105972 (Abbott)
    Vindesine A 204197 (Abbott)
    Dolastatine 10 (NCI) LU 223651 (BASF)
    Rhizoxine (Fujisawa) D 24851 (ASTA Medica)
    Mivobuline (Warner-Lambert) ER-86526 (Eisai)
    Cemadotine (BASF) Combretastatine A4 (BMS)
    RPR 109881A (Aventis) Isohomohalichondrin-B (PharmaMar)
    TXD 258 (Aventis)
    Epothilon B (Novartis) ZD 6126 (AstraZeneca)
    T 900607 (Tularik) PEG-Paclitaxel (Enzon)
    T 138067 (Tularik) AZ10992 (Asahi)
    Cryptophycin 52 (Eli Lilly) !DN-5109 (Indena)
    Vinflunine (Fabre) AVLB (Prescient NeuroPharma)
    Auristatine PE (Teikoku Hormone)
    Azaepothilon B (BMS)
    BMS 247550 (BMS) BNP- 7787 (BioNumerik)
    BMS 184476 (BMS) CA-4-Prodrug (OXiGENE)
    BMS 188797 (BMS) Dolastatin-10 (NrH)
    Taxoprexine (Protarga) CA-4 (OXiGENE)
    Aromatase inhibitors Aminoglutethimide Exemestane
    Letrozole Atamestane (BioMedicines)
    Anastrazole YM-511 (Yamanouchi)
    Formestane
    Thymidylatesynthas e inhibitors Pemetrexed (Eli Lilly) Nolatrexed (Eximias)
    ZD-9331 (BTG) CoFactor™ (BioKeys)
    DNA antagonists Trabectedine (PharmaMar) Mafosfamide (Baxter
    Glufosfamide (Baxter International) International)
    Apaziquone (Spectrum Pharmaceuticals)
    Albumin + 32P (Isotope Solutions)
    O6-Benzylguanine (Paligent)
    Thymectacine (NewBiotics)
    Edotreotide (Novartis)
    Farnesyltransferase inhibitors Arglabine (NuOncology Labs) Tipifarnibe (Johnson & Johnson)
    lonafarnibe (Schering-Plough)
    Perillylalcohol (DOR BioPharma)
    BAY-43-9006 (Bayer)
    Pump inhibitors CBT-1 (CBA Pharma) Zosuquidar-Trihydrochloride (Eli Lilly)
    Tariquidar (Xenova)
    MS-209 (Scherinq AG) Biricodar-Dicitrate (Vertex)
    Histoneacetyltransf erase inhibitors Tacedinaline (Pfizer) Pivaloyloxymethylbutyrate (Titan)
    SAHA (Aton Pharma)
    MS-275 (Schering AG) Depsipeptide (Fujisawa)
    Metalloproteinase inhibitors / Ribonucleosideredu ktase inhibitors Neovastat (Aeterna Laboratories) CMT -3 (CollaGenex)
    BMS-275291 (Celltech)
    Marimastat (British Biotech) Tezacitabine (Aventis)
    Galliummaltolate (Titan) Didox (Molecules for Health)
    Triapine (Vion)
    TNF-alpha agonists/ antagonists Virulizine (Lorus Therapeutics) Revimide (Celgene)
    CDC-394 (Celqene)
    Endotheline-A receptor antagonists Atrasentane (Abbot) YM-598 (Yamanouchi)
    ZD-4054 (AstraZeneca)
    Retinoic acid receptor agonists Fenretinide (Johnson & Johnson) Alitretinoin (Ligand)
    LGD-1550 (Ligand)
    Immunomodulators Interferon Dexosome therapy (Anosys)
    Oncophage (Antigenics) Pentrix (Australian Cancer Technology)
    GMK (Progenics)
    Adenocarzinoma vaccine (Biomira) JSF-154 (Tragen)
    Cancer vaccine (Intercell)
    CTP-37 (AVI BioPharma) Noreline (Biostar)
    JRX-2 (Immuno-Rx) BLP-25 (Biomira)
    PEP-005 (Peplin Biotech) MGV (Progenics)
    Synchrovax vaccine (CTL Immuno) 13-Alethine (Dovetail)
    CLL-Thera (Vasogen)
    Melanoma vaccine (CTL Immuno)
    p21-RAS vaccine (GemVax)
    Hormonal and anti-hormonal agents Estrogens Prednisone
    Conjugated Estrogens Methylprednisolone
    Ethinylestradiole Prednisolone
    Chlorotrianisen Aminoglutethimide
    Idenestrole Leuprolide
    Hydroxyprogesteroncaproate Goserelin
    Medroxyprogesterone Leuporelin
    Testosterone Cetrorelix
    Testosteronpropionate Bicalutamide
    Fluoxymesterone Flutamide
    Methyltestosterone Octreotide
    Diethylstilbestrole Nilutamide
    Megestrole Mitotane
    Tamoxifen P-04 (Novogen)
    Toremofine 2-Methoxyestradiol (EntreMed)
    Dexamethasone Arzoxifen (Eli Lilly)
    Photodynamic agents Talaporfine (Light Sciences) Pd-Bacteriopheophorbide (Yeda)
    Theralux (Theratechnologies)
    Motexafin Gadolinium (Pharmacyclics) Lutetium-Texaphyrine (Pharmacyclics)
    Hypericine
    Tyrosinkinase inhibitors Imatinib (Novartis) Kahalid F (PharmaMar)
    Leflunomid (Sugen/Pharmacia) CEP- 701 (Cephalon)
    CEP-751 (Cephalon)
    ZDI839 (AstraZeneca) MLN518 (Millenium)
    Erlotinib (Oncogene Science) PKC412 (Novartis)
    Canertjnib (Pfizer) Phenoxodiol O
    Squalamin (Genaera) Trastuzumab (Genentech)
    SU5416 (Pharmacia) C225 (ImClone)
    SU6668 (Pharmacia) rhu-Mab (Genentech)
    ZD4190 (AstraZeneca) MDX-H210 (Medarex)
    ZD6474 (AstraZeneca) 2C4 (Genentech)
    Vatalanib (Novartis) MDX-447 (Medarex)
    PKI166 (Novartis) ABX-EGF (Abgenix)
    GW2016 (GlaxoSmithKline) IMC-1C11 (ImClone)
    EKB-509 (Wyeth)
    EKB-569 (Wyeth)
    Different agents SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) BCX-1777 (PNP inhibitor, BioCryst)
    Tocladesine (cyclic-AMP agonist, Ribapharm) Ranpirnase (Ribonuclease stimulans, Alfacell)
    Alvocidib (CDK inhibitor, Aventis) Galarubicin (RNA synthesis inhibitor, Dong-A)
    CV-247 (COX-2-Inhibitor, Ivy Medical) Tirapazamin (reducing agent, SRI International)
    P54 (COX-2 inhibitor, Phytopharm) N-Acetylcystein (reducing agent, Zambon)
    CapCell™ (CYP450 stimulans, Bavarian Nordic) R-Flurbiprofen (NF-kappaB inhibitor, Encore)
    GCS-IOO (gal3 antagonist, GlycoGenesys) 3CPA (NF-kappaB inhibitor, Active Biotech)
    G17DT immunogen (Gastrin inhibitor, Aphton) Seocalcitol (Vitamin-D receptor agonist, Leo)
    Efaproxiral (Oxygenator, Allos Therapeutics) 131-I-TM-601 (DNA antagonist, TransMolecular)
    PI-88 (Heparanase inhibitor, Progen) Eflornithin (ODC inhibitor, ILEX Oncology)
    Tesmilifen (Histamine antagonist, YM BioSciences) Minodronic acid (Osteoclasts inhibitor, Yamanouchi)
    Histamine (Histamine-H2 receptor agonist, Maxim) Indisulam (p53 stimulans, Eisai)
    Tiazofurin (IMPDH inhibitor, Ribapharm) Aplidin (PPT inhibitor, PharmaMar)
    Cilengitide (Integrine antagonist, Merck KGaA) Rituximab (CD20 antibody, Genentech)
    SR-31747 (IL-1 antagonist, Sanofi-Synthelabo) Gemtuzumab (CD33 antibody, Wyeth Ayerst)
    CCI-779 (mTOR kinase inhibitor, Wyeth) PG2 (Hematopoesis enhancer, Pharmagenesis)
    Exisulind (PDE-V inhibitor, Cell Pathways) Immunol™ (Triclosan oral irrigation, Endo)
    CP-461 (PDE-V inhibitor, Cell Pathways) Triacetyluridine (Uridine prodrug, Wellstat)
    AG-2037 (GART inhibitor, Pfizer) SN-4071 (sarcoma agent, Signature BioScience)
    WX-UK1 (Plasminogen activator inhibitor, Wilex) TransMID-107™ (Immunotoxine, KS Biomedix)
    PBI-1402 (PMN stimulans, ProMetic LifeSciences)
    PCK-3145 (Apoptosis enhancer, Procyon)
    Bortezomib (Proteasome inhibitor, Millennium)
    Doranidazole (Apoptosis enhancer, Pola)
    SRL-172 (T-cell stimulans, SR Pharma)
    CHS-828 (cytotoxic agent, Leo)
    TLK-286 (Glutathione-S-transferase inhibitor, Telik)
    trans-Retinoic acid (Differentiator, NIH)
    PT-100 (Growth factor agonist, Point Therapeutics)
    MX6 (Apoptosis enhancer, MAXIA)
    Midostaurin (PKC inhibitor, Novartis)
    Apomin (Apoptosis enhancer, ILEX Oncology)
    Bryostatin-1 (PKC stimulans, GPC Biotech)
    Urocidine (Apoptosis enhancer, Bioniche)
    CDA-II (Apoptosis enhancer, Everlife)
    Ro-31-7453 (Apoptosis enhancer, La Roche)
    SDX-101 (Apoptosis enhancer, Salmedix)
    Brostallicin (Apoptosis
    Ceflatonin (Apoptosis enhancer, ChemGenex) enhancer, Pharmacia)
  • In a preferred embodiment, a compound of the invention is administered in combination with one or more known anti-tumor agents, such as the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxics, antiproliferative agents, prenyl proteintransferase inhibitors, HMG-CoA-reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, angiogenesis inhibitors.
  • The compounds of the invention are in particular well suited for administration in combination with radiotherapy. The synergistic effects of VEGF inhibition in combination with radiotherapy are known to the skilled artisan ( WO 00/61186 ).
  • The term "estrogen receptor modulators" in the course of the present invention refers to compounds that interfere with or inhibit the binding of estrogen to estrogen receptor - independently from the mode of action. Non-limiting examples of estrogen receptor modulators are tamoxifen, raloxifen, idoxifen, LY353381, LY 117081, toremifen, fulvestrant, 4-[7-(2,2-Dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl-2,2-dimethyl-propanoate, 4,4'-Dihydroxybenzophenon-2,4-dinitrophenylhydrazone and SH646.
  • The term "androgen receptor modulators" in the course of the present invention refers to compounds that interfere with or inhibit the binding of androgens to androgen receptor - independently from the mode of action. Non-limiting examples of androgen receptor modulators are finasteride and other 5alpha-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abirateron acetate.
  • The term "retinoid receptor modulators" in the course of the present invention refers to compounds that interfere with or inhibit the binding of retinoids to retinoid receptor - independently from the mode of action. Non-limiting examples of retinoid receptor modulators are bexaroten, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, alpha-difluoromethylornithine, ILX23-7553, trans-N-(4'-Hydroxyphenyl)retinamide and N-4-carboxyphenylretinamide.
  • The term "cytotoxics" in the course of the present invention refers to compounds that primarily trigger cell death through direct action on cell function(s) or which interfere with or inhibit cell myosis, such as alkylating agents, tumor necrosis factors, intercalating agents, microtubule inhibitors and topoisomerase inhibitors. Non-limiting examples of cytotoxics are tirapazimin, sertenef, cachectine, ifosfamide, tasonermine, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcit, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustin, improsulfan-tosylate, trofosfamide, nimustine, dibrospidium-chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-amindichloro(2-methylpyridine)platin, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platin(II)]bis-[diamine(chloro)platin(II)]-tetrachloride, diarizidinylspermine, arsenium trioxide, 1-(11-Dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantren, mitoxantron, pirarubicin, pinafide, valrubicine, amrubicine, antineoplaston, 3'-desamino-3'-morpholino-13-desoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755 and 4-desmethoxy-3-desamino-3-aziridinyl-4-methylsulfonyl-daunorubicin ( WO 00/50032 ).
  • Non-limiting examples of microtubule inhibitors are paclitaxel, vindesine-sulfate, 3',4'-dideshydro-4'-desoxy-8'-norvincaleukoblastine, docetaxol, rhizoxine, dolastatine, mivobuline-isethionate, auristatine, cemadotine, RPR109881, BMS184476, vinflunine, cryptophycine, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)-benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.
  • Non-limiting examples of topoisomerase inhibitors are topotecane, hycaptamine, irinotecane, rubitecane, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusine, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo-[de]-pyrano-[3',4':b,7]indolizino[1,2b]quiinoline-10,13(9H,15H)-dione, lurtotecane, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecine, BNP1350, BNPI1100, BN80915, BN80942, etoposide-phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-desoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexohydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylendioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-aminoethyl)amino]-benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]-acridine-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxane-then-4-ylmethyl]formamide, N-(2-(dimethyl-amino)-ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)-ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one and dimesna.
  • Non-limiting examples of antiproliferative agents are antisense RNA- and antisense-DNA oligonucleotides, such as G3139, ODN698, RVASKRAS, GEM231 and INX3001, as well as antimetabolites scuh as enocitabine, carmofur, tegafur, pentostatine, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabin-ocfosfate, fosteabine sodiumhydrate, raltitrexed, paltitrexide, emitefur, tiazofurine, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-desoxy-2'-methylidencytidine, 2'-fluoromethylen-2'-desoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-desoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ecteinascidine, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazine-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutaminic acid, aminopterine, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diaza-tetracyclo-(7.4.1.0.0)-tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexole, dexrazoxane, methioninase, 2'-cyan-2'-desoxy-N4-palmitoyl-1-B-D-arabinofuranosylcytosine and 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone.
  • "Antiproliferative agents" also comprises monoclonal antibodies against growth factors that have not been listed under "angiogenesis inhibitors", such as trastuzumab, as well as tumor suppressor genes, such as p53.
  • In another aspect of the invention, a medicament according to above aspects and embodiments is provided, wherein in such medicament comprises at least one additional pharmacologically active substance (drug, ingredient).
  • In a preferred embodiment the at least one pharmacologically active substance is a substance as described herein.
  • In another aspect of the invention, a medicament according to above aspects and embodiments is provided, wherein the medicament is applied before and/or during and/or after treatment with at least one additional pharmacologically active substance.
  • In a preferred embodiment the at least one pharmacologically active substance is a substance as described herein.
  • In another aspect of the invention, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the invention is provided.
  • In a preferred embodiment, the pharmaceutical composition contains at least one additional compound selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, diluents, carriers and/or additional pharmaceutically active substance other than the compounds of the invention.
  • In another aspect of the invention, a pharmaceutical composition is disclosed which comprises at least one compound of the invention, at least one pharmacologically active substance other than the compounds of the invention as described herein; and a pharmaceutically acceptable carrier.
  • A further embodiment of the present invention is a process for the manufacture of said pharmaceutical compositions, characterized in that one or more compounds according to the invention and one or more compounds selected from the group consisting of solid, liquid or semiliquid excipients, auxiliaries, adjuvants, diluents, carriers and pharmaceutically active agents other than the compounds according to the invention, are converted in a suitable dosage form.
  • In another aspect of the invention, a kit is provided comprising a therapeutically effective amount of at least one compound of the invention and/or at least one pharmaceutical composition as described herein and a therapeutically effective amount of at least one further pharmacologically active substance other than the compounds of the invention.
  • The pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal, transocular, subcutaneous, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. Parenteral administration is preferred. Oral administration is especially preferred.
  • Suitable dosage forms include, but are not limited to capsules, tablets, pellets, dragees, semi-solids, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, which can be produced according to methods known in the art, for example as described below:
    • tablets: mixing of active ingredient/s and auxiliaries, compression of said mixture into tablets (direct compression), optionally granulation of part of mixture before compression.
    • capsules: mixing of active ingredient/s and auxiliaries to obtain a flowable powder, optionally granulating powder, filling powders/granulate into opened capsules, capping of capsules.
    • semi-solids (ointments, gels, creams): dissolving/dispersing active ingredient/s in an aqueous or fatty carrier; subsequent mixing of aqueous/fatty phase with complementary fatty/ aqueous phase, homogenization (creams only).
    • suppositories (rectal and vaginal): dissolving/dispersing active ingredient/s in carrier material liquified by heat (rectal: carrier material normally a wax; vaginal: carrier normally a heated solution of a gelling agent), casting said mixture into suppository forms, annealing and withdrawal suppositories from the forms.
    • aerosols: dispersing/dissolving active agent/s in a propellant, bottling said mixture into an atomizer.
  • In general, non-chemical routes for the production of pharmaceutical compositions and/or pharmaceutical preparations comprise processing steps on suitable mechanical means known in the art that transfer one or more compounds of the invenion into a dosage form suitable for administration to a patient in need of such a treatment. Usually, the transfer of one or more compounds of the invention into such a dosage form comprises the addition of one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds of the invention. Suitable processing steps include, but are not limited to combining, milling, mixing, granulating, dissolving, dispersing, homogenizing, casting and/or compressing the respective active and non-active ingredients. Mechanical means for performing said processing steps are known in the art, for example from Ullmann's Encyclopedia of Industrial Chemistry, 5th Edition. In this respect, active ingredients are preferably at least one compound of the invention and one or more additional compounds other than the compounds of the invention, which show valuable pharmaceutical properties, preferably those pharmaceutical active agents other than the compounds of the invention, which are disclosed herein.
  • Particularly suitable for oral use are tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal use are suppositories, suitable for parenteral use are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical use are ointments, creams or powders. The compounds of the invention may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations. The preparations indicated may be sterilised and/or comprise assistants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
  • Suitable excipients are organic or inorganic substances, which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the compounds of the invention, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose, sucrose, mannitol, sorbitol or starch (maize starch, wheat starch, rice starch, potato starch), cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, magnesium stearate, talc, gelatine, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, polyvinyl pyrrolidone and/or vaseline.
  • If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries include, without limitation, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings, which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices or to provide a dosage form affording the advantage of prolonged action, the tablet, dragee or pill can comprise an inner dosage and an outer dosage component me latter being in the form of an envelope over the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, acetyl alcohol, solutions of suitable cellulose preparations such as acetyl-cellulose phthalate, cellulose acetate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly. In particular, tablets, coated tablets, capsules, syrups, suspensions, drops or suppositories are used for enteral administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The compounds of the invention can also be lyophilized and the lyophilizates obtained can be used, for example, for the production of injection preparations.
  • The preparations indicated can be sterilized and/or can contain excipients such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colorants, flavourings and/or aromatizers. They can, if desired, also contain one or more further active compounds, e.g. one or more vitamins.
  • Other pharmaceutical preparations, which can be used orally include push-fit capsules made of gelatine, as well as soft, sealed capsules made of gelatine and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
  • The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatine.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400).
  • Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran, optionally, the suspension may also contain stabilizers.
  • For administration as an inhalation spray, it is possible to use sprays in which the active ingredient is either dissolved or suspended in a propellant gas or propellant gas mixture (for example CO2 or chlorofluorocarbons). The active ingredient is advantageously used here in micronized form, in which case one or more additional physiologically acceptable solvents may be present, for example ethanol. Inhalation solutions can be administered with the aid of conventional inhalers.
  • Possible pharmaceutical preparations, which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatine rectal capsules, which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
  • For use in medicine, the compounds of the present invention will be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic bases, e.g. quaternary ammonium salts.
  • The pharmaceutical preparations can be employed as medicaments in human and veterinary medicine. As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function. Said therapeutic effective amount of one or more of the compounds of the invention is known to the skilled artisan or can be easily determined by standard methods known in the art.
  • The compounds of the invention and the additional active substances are generally administered analogously to commercial preparations. Usually, suitable doses that are therapeutically effective lie in the range between 0.0005 mg and 1000 mg, preferably between 0.005 mg and 500 mg and especially between 0.5 mg and 100 mg per dose unit. The daily dose is preferably between about 0.001 mg/kg and 10 mg/kg of body weight.
  • Those of skill will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Some of the specific compounds are more potent than others. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means. A preferred means is to measure the physiological potency of a given compound.
  • For the purpose of the present invention, all mammalian species are regarded as being comprised. In a preferred embodiment, such mammals are selected from the group consisting of "primate, human, rodent, equine, bovine, canine, feline, domestic animals, cattle, livestock, pets, cow, sheep, pig, goat, horse, pony, donkey, hinny, mule, hare, rabbit, cat, dog, guinea pig, hamster, rat, mouse". More preferably, such mammals are humans. Animal models are of interest for experimental investigations, providing a model for treatment of human diseases.
  • The specific dose for the individual patient depends, however, on the multitude of factors, for example on the efficacy of the specific compounds employed, on the age, body weight, general state of health, the sex, the kind of diet, on the time and route of administration, on the excretion rate, the kind of administration and the dosage form to be administered, the pharmaceutical combination and severity of the particular disorder to which the therapy relates. The specific therapeutic effective dose for the individual patient can readily be determined by routine experimentation, for example by the doctor or physician, which advises or attends the therapeutic treatment.
  • In the case of many disorders, the susceptibility of a particular cell to treatment with the subject compounds may be determined by in vitro testing. Typically a culture of the cell is combined with a subject compound at varying concentrations for a period of time sufficient to allow the active agents to show a relevant reaction, usually between about one hour and one week. For in vitro testing, cultured cells from a biopsy sample may be used.
  • Even without further details, it is assumed that a person skilled in the art will be able to utilise the above description in the broadest scope. The preferred embodiments should therefore merely be regarded as descriptive disclosure, which is absolutely not limiting in any way.
  • Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means that, if necessary, the solvent is removed, water is added if necessary, the pH is adjusted, if necessary, to between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is washed with saturated NaHCO3 solution, if desired with water and saturated NaCl solution, is dried over sodium sulfate, filtered and evaporated, and the product is purified by chromatography on silica gel, by preparative HPLC and/or by crystallisation. The purified compounds are, if desired, freeze-dried.
    Mass spectrometry (MS): ESI (electrospray ionisation) (M+H)+
    • List of Abbreviations and Acronyms:
  • AcOH acetic acid, anh anhydrous, atm atmosphere(s), BOC tert-butoxycarbonyl CDI 1,1'-carbonyl diimidazole, conc concentrated, d day(s), dec decomposition, DMAC NN-dimethylacetamide, DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(IH)-pyrimidinone, DMF NN-dimethylformamide, DMSO dimethylsulfoxide, DPPA diphenylphosphoryl azide, EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, EtOAc ethyl acetate, EtOH ethanol (100%), Et2O diethyl ether, Et3N triethylamine, h hour(s), MeOH methanol, pet. ether petroleum ether (boiling range 30-60°C), temp. temperature, THF tetrahydrofuran, TFA trifluoroAcOH, Tf trifluoromethanesulfonyl.
  • The invention is explained in more detail by means of the following examples.
    • Examples I. Synthesis of selected compounds of the invention
  • The following compounds were synthesized and characterized. However, it lies in the knowledge of a person skilled in the art to prepare and characterize these compounds differently.
    • Example 1 Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 6
  • Figure imgb0102
    • a. Synthesis of 2-Amino-3-carbamoyl-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid tert-butyl ester (3)
  • Starting material 1 (25 g, 125 mmol) was suspended in a 250 ml bowl flask in 125 ml abs. ethanol and mixed with starting material 2 (10.5 g, 125 mmol) and sulfur (4.023 g, 125 mmol). 12.9 ml (125 mmol) diethyl amine was added dropwise to the yellow suspension, which thereby became of orange color. The reaction mixture was stirred over night at ambient temperature. Next day, the reddish solution was concentrated in vacuo and the crude product was re-crystallized in methanol. The desired product 3 was isolated as a red-brown solid (40.7 g, 116 mmol, 93%).
    • b. Synthesis of 3-Carbamoyl-2-[3-(4-chloro-phenyl)-ureido]-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid tert-butyl ester (4)
  • Compound 3 (1.5 g, 4.3 mmol) and p-Chlorphenylisocyanat (724 mg, 4.7 mmol) were dissolved in pyridine (12 ml) and stirred over night at room temperature. Another equivalent of isocyanate (724mg, 4.7 mmol) was added and the mixture was stirred over the weekend. The solvent was reduced under vacuum and the crude product (2.3 g, 4 mmol; light brown solid) was used in the next reaction without further purification (Content: 79% compound 4 according to UV).
    • c. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (5)
  • Starting material 4 (2.3 g, 4.1 mmol) was suspended in 20 ml DCM and mixed with trifluoro acetic acid (TFA, 7.9 ml, 102 mmol). The resulting brown solution was stirred at room temperature for 50 Min. the solvent was reduced in vacuo and the crude product was purified by prep. HPLC (Method 1).
  • The product fraction were merged and the solvent was reduced and the product finally lyophilized yielding 5 (850 mg, 2.4 mmol, 59%) as a light brown solid.
    • d. Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (6)
  • Starting material 5 (847 mg, 2.4 mmol) was suspended in DMF (8 ml) and 1 H-1,2,3-benzotiazole-5-carboxyllic acid (473 mg, 2.9 mmol), dry HOBt (427 mg, 2.9 mmol) and EDCI (606 mg, 2.9 mmol) were added. The brown suspension was stirred at ambient temperature over the weekend. As the reaction was not complete yet, the reaction was further stirred at 80° for 4 h. Thereby a brown solution was formed. The solvent was evaporated in vacuo and the crude product was further purified by prep. HPLC (Method 1). The product fractions were merged, the solvent was evaporated and the product lyophilized. Thereby 310 mg of the desired product 6 (0.635 mmol, 28%) were isolated as a light brown solid and additional 58 mg of the same product with 76 % content which could have been purified further.
  • As an alterative, 5 can be prepared by using an alloc-protected starting material instead of the BOC-protected one:
    Figure imgb0103
    • e. Synthesis of 2-Amino-3-carbamoyl-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid allyl ester (8)
  • Starting materials 7 (4 g, 22 mmol), 2 (1.8 g, 22 mmol) and sulfur (700 mg, 22 mmol) were weighed into a bowl flask and 16 ml of ethanol were added. Diethyl amine (2.2 ml, 22 mmol) was added dropwise to the yellow suspension. The reaction was stirred over night. The orange colored precipitate was filtered off and identified as the product 8 (4 g, 11.8 mmol, 83% content, 54% yield) which could be used without further purification.
    • f. Synthesis of 3-Carbamoyl-2-[3-(4-chloro-phenyl)-ureido]-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid allyl ester (9)
  • Starting material 8 (1 g, 3.6 mmol) was dissolved in 12 ml of pyridine and p-chlorphenyl isocyanate (546 mg, 3.6 mmol) was added. The red solution was stirred over the weekend. The solvent was reduced in a vacuum centrifuge. The crude product was used without further purification (green-brown solid, 1.13 g, 65% content 9, 46 % yield).
    • g. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (5)
  • Starting material 9 (750 mg, 1.7 mmol) was dissolved under Nitrogen atmosphere in 10 ml DCM in a 2 necked flask and a solution of morpholine (3 ml, 34.5 mmol) in 34.5 ml DCM was added. The solution was stirred for 5 Min. then a solution of Tetrakis(triphenylphosphin)-palladium(0) (199 mg, 0.2 mmol) in 17.2 ml DCM was added. After about 8 Min a brown suspension was formed. The reaciton was stirred at ambient temperature for another 40 Min. The solvent was then reduced and product 5 was thereby isolated in two fractions: very pure as white crystals (246 mg, 0.7 mmol, 41%) and with 56 % content in a brown solid (250 mg, 56% Gehalt an 5, 0.4 mmol), which contained side products as well but could be purified by prep. HPLC (Method 2). The pure product fractions were merged, the solvent reduced and the product lyophilized.
  • As an alterative, as exemplified in example 2, the final products can be prepared without the use of any protecting group:
    • Example 2 Synthesis of 1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea (14)
  • Figure imgb0104
    • a. Synthesis of (2-Amino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-3-yl)-pyrrolidin-1-yl-methanone (12)
  • In a 100ml bowl flask with dropping funnel, pyridon-(4) (starting material 10, 1 g, 10.1 mmol) was dissolved in 50 ml abs. ethanol. Then starting material 11 (1.4 g, 10.1 mmol) and sulfur (0.3 g, 10.1 mmol) were added. 2 ml diethyl amine (20.2 mmol) were added dropwise to the yellow suspension (over 20 Min) resulting in a brown solution. The reaction was stirred at room temperature over night. Another ml of Diethyl amine (10.1 mmol) was added and the reaction was stirred for another 7 h. The reaction was concentrated in vacuo. Thereby the desired product 12 was isolated as a viscous brown matter (3.2 g, 75% content of 12, 95% yield), which could be used without further purification.
    • b. Synthesis of [2-Amino-6-(1H-benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-3-yl]-pyrrolidin-1-yl-methanone (13)
  • Starting material 12 (1.6 g, 6.4 mmol) was dissolved in 20 ml DMF. Then EDCI (1.46 g, 7.6 mmol) and HOBt (1.3 g, 9.5 mmol) were added. Now, one half of 1.04 g (6.4 mmol) 1 H-1,2,3-benzotiazole-5-carboxyllic acid was added. The reaction mixture was stirred at ambient temperature over night. Then the other half of the 1 H-1,2,3-benzotiazole-5-carboxyllic acid was added and the reaction mixture was again stirred at ambient temperature over night. The reaction mixture was now concentrated in vacuo yielding 7 g crude product. Those were taken up in ethyl acetate and water and the phases were separated. The organic phase was washed with water and the combined aqueous phases were washed with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo. The desired product 13 was isolated as a brown oil (1.2 g, 20% content, 10 % yield).
    • c. Synthesis of 1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea (14)
  • Starting material 13 (1.2 g, 20 % content, 0.6 mmol) was dissolved in 5 ml pyridine and one half of 112 mg (0.7 mmol) p-chlorphenyl isocyanate was added. The reaction mixture was stirred over night at ambient temperature. Then the other half of the p-chlorphenyl isocyanate was added and the reaction was again stirred over night at ambient temperature. The reaction was now concentrated in vacuo and the thereby isolated crude product was dissolved in 7 ml DMSO and purified by prep. HPLC (Method 3). The pure fractions were combined, the solvent reduced and the product finally lyophilized. The desired product 14 could thereby be isolated as yellow solid (16.2 mg, 4%; and additional 17 mg, 84% content 14, 4 % yield).
  • In analogy to example 2-a, pyridon(4)-hydrochloride (15) was reacted with cyano-acetic acid methyl ester (16):
    Figure imgb0105
    • a.' Synthesis of 2-Amino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester hydrochloride (17)
  • Piperidone-(4), hydrochloride (15, 154 g, 1.1 mol), Methyl-cyanacetat (16, 84 g, 0.8 mol) and sulfur (32 g, 1 mol) were suspended in 500 ml methanol. Then diethyl amine (150 ml, 1.4 mol) was added. The mixture was stirred at room temperature for 5 h. The resulting crystals were filtered, washed with a mixture of iso-propanol and methanol and dried. The mother liquor was reduced to 50 % volume in vacuo and left over night. The resulting crystals were again filtered, washed with iso-propanol and dried. In total 133 g of the desired product 17 (0.54 mol, 47%) were isolated, characterized by NMR and further used in reactions in analogy to 12.
  • Instead of ureas also amides were synthesized:
    • Example 3: Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluoro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide
  • Figure imgb0106
    • a. Synthesis of 3-Carbamoyl-2-[2-(4-chloro-2-fluoro-phenyl)-acetylamino]-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid tert-butyl ester (19)
  • Starting material 3 (1 g, 2.9 mmol) was suspended in 11 ml DMF and starting material 18 (593 mg, 3.1 mmol), dry HOBt (505 mg, 3.1 mmol) and EDCI (657 mg, 3.4 mmol) were added. The brown suspension was stirred over the weekend at ambient temperature then the reaction was heated to 80°C over night. The solvent was reduced in the vacuum centrifuge and the crude product (a brown oil) was used without further purification (3.2 g, 22% content 19, 53% yield).
    • b. Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (20)
  • Starting material 19 (3.2 g, 22% content, 1.5 mmol) was dissolved in 25 ml dried DCM and trifluoro acetic acid (TFA, 8.0 ml, 104 mmol) was added. The reaction was stirred at ambient temperature for 30 Min. The solvent was reduced in vacuo and the crude product was purified at the Flashmaster (Method 1). The isolated product was not sufficiently pure and was therefore purified again at the prep. HPLC (Method 4). The pure fractions were combined and the solvent was reduced. The desired product 20 was thereby isolated as a brown solid (236 mg, 42%).
    • c. Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluoro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (21)
  • Starting material 20 (118 mg, 0.3 mmol) was suspended in 2 ml dry DMF and 1H-1,2,3-benzotiazole-5-carboxyllic acid (63 mg, 0.4 mmol, 1.2 equiv.), dry HOBt (52 mg, 0.4 mmol) and EDCI (74 mg, 0.4 mmol) were added. The brown suspension was stirred at 80°C over night. Then another 0.5 equiv. 1H-1,2,3-benzotiazole-5-carboxyllic acid were added and the reaction was stirred another 6h at 80°C. the solvent was reduced under vacuo and the remaining crude product further purified by prep. HPLC (Method 3). The pure fractions were combined and the solvent was reduced. The remaining product was lyophilized yielding the desired products 21 as a light-brown solid (20 mg, 0.04 mmol, 12 %).
  • Analogously, instead of making amides with 1H-1,2,3-benzotiazole-5-carboxylic acid other substituents were introduced as well:
    • Example 4: Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (23)
  • Figure imgb0107
    • Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (23)
  • Amine 20 (168 mg, 0.5 mmol) and aldehyde 22 (0.1 ml, 0.5 mmol) were dissolved in 1,2-Dichloroethan (5 ml) and dry THF (5 ml). 51µl glacial acetic acid (0.9 mmol) were added and the suspension was stirred for 3 h at ambient temperature. Now 305 mg NaB(OAc)3 (1.4 mmol) and another 51µl glacial acetic acid (0.9 mmol) were added and the reaction was stirred at room temperature over night. The resulting solid was filtered off. The mother liquid contained the product and was thus concentrated yielding 400 mg crude product which was further purified by prep. HPLC (Method 4). 26 mg of the desired product 23 were isolated as brown amorphous solid (12 %).
    • Example 5: Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide] (32)
  • Figure imgb0108
    • a. Synthesis of 4-Fluoro-3-nitro-benzoic acid methyl ester (25)
  • Starting material 24 (10 g, 54 mmol) was placed in 60 ml methanol and 0.5 ml sulfuric acid was added dropwise. Now the reaction was stirred over night at 80 °C. The reaction mixture was then distributed between water and ethyl acetate. The combined organic phases were dried over MgSO4, filtered and concentrated yielding the desired product 25 quantitatively as amorphous solid (10.8 g, 54 mmol).
    • b. Synthesis of 4-(Carbamoyl-cyano-methyl)-3-nitro-benzoic acid methyl ester (27)
  • Starting material 25 (10 g, 50 mmol) and cyanacetamide (26, 8.4 g, 100 mmol) were dissolved in dry THF and NaH (60%ig, 4 g, 100 mmol) was added. The reaction was stirred over night at ambient temperature. Now it was cooled to 0°C and 4 N HCI/Dioxan was added. The reaction mixture was concentrated in vacuo, the solid residue crystallized with 400ml isopropyl ethyl ether, resulting crystals were filtered and dried. Then the crystals were washed with water and again filtered and dried. Thereby 8.9 g of the desired product 27 (67 %, 34 mmol) were isolated.
    • c. Synthesis of 4-Fluoro-3-amino-benzoic acid methyl ester (28)
  • Starting material 27 (7 g, 26.6 mmol) was dissolved in 700 ml methanol. The solution was hydrogenated in tow batches in the H-cube (Thales Nanotechnology).
    • Parameters:
  • flow rate: 3,0ml/min
    mode full H2
    catalyst Raney Nickel THS 01122
    T/°C R.T.
    p/bars ambient pressure
  • The hydrogenated solutions were combined and reduced in vacuo. The product isolated thereby (28, 5.5 g, 23.5 mmol, 89%) was used further without additional purification.
    • d. Synthesis of 2-Amino-3-carbamoyl-1 H-indole-6-carboxylic acid (29)
  • Starting material 28 (5.5 g, 23.5 mmol) was dissolved in 200 ml abs. THF and 2 N NaOH (45 ml, 90 mmol) was added at room temperature. Upon stirring, the solution got dark and a solid precipitate was formed. The suspension was reduced to about 100 ml and extracted three times with 400ml ethyl acetate each. The aqueous phase was reduced in vacuo and treated twice with ethyl acetate upon which the desired product 29 was crystallized (1.1 g, 5.5 mmol, 21%).
    • e. Synthesis of 2-Amino-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide] (31)
  • Starting material 29 (500 mg, 2.3 mmol) was dissolved in 2 ml dry DMF. Then EDCI (575 mg, 3 mmol) and HOBt (322 mg, 2.4 mmol) were added. The reaction was stirred over night at ambient temperature. Now the reaction mixture was poured into water and the resulting precipitate was filtered and dried. This intermediate was identified to be the HOBT ester of the starting material 29 (645 mg, 1.9 mmol, 84%), which could be used without further purification:
    • 500 mg (1.5 mmol) of the intermediate and 300.3 mg (2 mmol) 6-Amino-3H-benzooxazol-2-one (preparation see below) were dissolved in dry DMF (2 ml). Then 383 mg (2 mmol) EDCI were added and the reaction was stirred at 60 °C over night. Now the solution was added to water and the resulting dark precipitate was filtered and dried yielding 400 mg (0.85 mmol) of the desired product 31 in 43 % yield (calculated from the used intermediate).
    f. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide] (32)
  • Starting material 31 (100 mg, 0.3 mmol) was dissolved in 1 ml dry pyridine. 4-Chlorphenyl isocyanate (46 mg, 0.3 mmol) was then added and the mixture stirred at ambient temperature. Then another 40 mg (0.29 mmol) 4-Chlorphenyl isocyanate were added and the reaction was stirred at 50 °C. After a few hours the reaction was reduced in vacuo and purified by prep. HPLC. After concentration of the pure fractions 10 mg (0.02 mmol, 7%) of the desired product 32 were isolated.
    • g. Synthesis of 6-Amino-3H-benzooxazol-2-one (30)
  • 5 g (26.9 mmol) 6-Nitrobenoxazol-2(3H)-on were dissolved in 100 ml THF and 1 g Pd-C-5% (containing 50.5% water) were added. The reaction was hydrogenated with H2 over 16 h. The reaction mixture was then filtered over celite and reduced in vacuo. Thereby the desired product 30 was isolated as a red-brown solid (2.6 g, 17.4 mmol, 65%).
    • Example 6: Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide (36)
  • Figure imgb0109
    • a. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid ethyl ester (34)
  • Starting material 33 (400 mg, 1.8 mmol) was dissolved in dry pyridine (1 ml). 4-Chlorphenylisocyanat (307 mg, 2 mmol) was added and the reaction was stirred at ambient temperature over night. The reaction mixture was then added to 1 N HCl and the resulting precipitate was filtered, washed with water and dried. The desired product 36 was thus isolated (710 mg, 1.58 mmol, 88 %).
    • b. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (35)
  • 505 mg (4.5 mmol) potassium-tert-butylat was placed in a bowl flask and 90 ml water were added, yielding finely dispersed KOH. Starting material 34 (710 mg, 1.6 mmol) was added to this suspension and the mixture was stirred at ambient temperature. After 3h the reaction was heated to 60 °C over night. Then 4.5ml 1 N HCl were added to the suspension and the mixture was concentrated in vacuo yielding a solid. Thereby the desired product 35 was isolated as a mixture with NaCl (800 mg, 45 % content, 1.035 mmol, 65 % yield) which could be used without further purification.
    • c. Synthesis of 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide (36)
  • Starting material 35 (300 mg, 45 % content, 0.4 mmol) and 6-Amino-3H-benzooxazol-2-one (30, 58 mg, 0.4 mmol) were dissolved in 2 ml of dry DMF. Then EDCI (96 mg, 0.5 mmol) and HOBt (76 mg, 0.5 mmol) were added. The reaction was stirred at ambient temperature over night. It was then purred into water and the resulting precipitate was filtered. The isolated precipitate was then stirred in 100 ml warm methanol and the non-soluble crystals filtered and washed with methanol. Thereby the desired product 36 (130 mg, 0.271 mmol, 70%) could be isolated.
    • Example 7: Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide (38)
  • Figure imgb0110
    • a. Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (37)
  • Starting material 18 (100 mg, 0.5 mmol) was dissolved in 2 ml DMF. Now EDCI (125 mg, 0.7 mmol) and HOBt (99 mg, 0.7 mmol) were added. After stirring 3 h at room temperature, starting material 33 (103 mg, 0.5 mmol) was added and the reaction was stirred 48 h at room temperature. The solution was poured into 1 N HCl and the resulting precipitate was filtered and dried yielding the desired product 37 (60 mg, 0.2 mmol, 70 % content, 31 % yield).
    • b. Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide (38)
  • Starting material 37 (60 mg, 0.2 mmol, 70 % content) and 6-Amino-3H-benzooxazol-2-one (30, 25 mg, 0.2 mmol) were dissolved in 2 ml DMF. Then EDCI (38 mg, 0.2 mmol) and HOBt (31 mg, 0.2 mmol) were added. The reaction was stirred over night at ambient temperature, concentrated in vacuo and purified by prep HPLC (Method 1). By concentration of the pure fractions the desired product 38 (23mg, 0.04 mmol, 24 %) could be isolated.
    • Example 8: Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide (43)
  • Figure imgb0111
    • a. Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (40)
  • Starting material 39 (1.7 g, 6.4 mmol), 4-methyl morpholine (700 µL, 6.4 mmol) and 1 H-1,2,3-benzotiazole-5-carboxyllic acid (1 g, 6.4 mmol) were dissolved in 15 ml DMF. Then EDCI (1.2 g, 6.4 mmol) and HOBt (0.9 g, 6.4 mmol) were added. The reaction was stirred over night at ambient temperature. Then water was added to the reaction mixture and stirring was continued. As no precipitate was formed, ethyl acetate was added and the phases were separated. The aqueous phase was washed twice with ethyl acetate. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuo.
  • The desired product 40 was isolated quantitatively (2.6 g, 6.4 mmol) and further used without purification.
    • b. Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (41)
  • Starting material 40 (2.6 g, 6.4 mmol) was mixed with 2 N NaOH (15 ml) and ethanol (15 ml) and stirred at ambient temperature. Additional 15ml 2 N NaOH were added. After the reaction was completed, the mixture was reduced to dryness, the solid was dissolved in water, adjusted to pH 2 with 2N HCl and the resulting precipitate was filtered and dried. Thus the desired product 41 (1.4 g, 4.4 mmol, 57 %) could be isolated as solid.
    • c. Synthesis of 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide (43)
  • Starting material 41 (171.3 mg, 0.5 mmol), 4-Methylmorpholin (60,3 µL, 0.5 mmol) and starting material 42 (85 mg, 0.5 mmol) were dissolved in 5 ml DMF. Then EDCI (105 mg, 0.5 mmol) and HOBt (74 mg, 0.5 mmol) were added. The reaction was stirred over night at ambient temperature.
  • The reaction mixture was poured into water and the resulting precipitate was filtered off. It was stirred in methyl tert-butyl ether and again filtered. Further purification was done by chromatography with a "Companion" (Method 1).
  • The pure fractions were concentrated, stirred in methyl tert-butyl ether and filtered. The desired product 43 could thereby be isolated (45.6 mg,0.1 mmol, 18%).
    • Example 9: Synthesis of [2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester (48)
  • Figure imgb0112
    • a. Synthesis of 6-(3,5-Dichloro-benzyloxycarbonylamino)-3,4-dihydro-1 H-isoquinoline-2-carboxylic acid tert-butyl ester (46)
  • Starting material 45 (250 mg, 1.4 mmol) and 1,1'-carbonyl diimidazol (275 mg, 1.7 mmol) were dissolved in 2 ml DCM and stirred at room temperature for 3 h. Then starting material 44 (350 mg, 1.4 mmol) was added and the resulting mixture was stirred over night at room temperature. The reaction mixture was diluted with ethyl acetate, the organic phase was washed with water 3 times, dried over Na2SO4, filtered and concentrated in vacuo. The remaining solid was purified over the prep. HPLC (Method 1), pure fractions were combined and concentrated in vacuo yielding the desired product 46 as brown solid (170 mg, 0.377 mmol, 27%).
    • b. Synthesis of (1,2,3,4-Tetrahydro-isoquinolin-6-yl)-carbamic acid 3,5-dichloro-benzyl ester (47)
  • Starting material 46 (170 mg, 0.4 mmol) was dissolved in 5 ml propanol. Then 1 ml HCl in 2-propanol (5-6 N) was added and the mixture was stirred over night at ambient temperature. The reaction mixture was then diluted with diethyl ether, concentrated in vacuo and stirred with diethyl ether, repeatedly decanting. Finally the solid residue was filtered off and dried in vacuo at 45 °C. Thus the desired product 47 was isolated as brownish crystals (46 mg, 0.1 mmol, 35 %).
    • c. Synthesis of [2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester (48)
  • Starting material 47 (46 mg, 0.1 mmol), 1H-1,2,3-benzotiazole-5-carboxyllic acid (22 mg, 0.1 mmol) and 4-methyl morpholin (40 µL, 0.4 mmol) were dissolved in 2 ml DMF. Then EDCI (38 mg, 0.2 mmol) and HOBt (26 mg, 0.2 mmol) were added and the mixture was stirred over night at ambient temperature. The reaction mixture was mixed with water and the resulting precipitate was filtered and dried in vacuo at 45 °C. The desired product 48 could thereby be isolated as light brown solid (34 mg, 0.07 mmol, 52 %).
    • Example 10: Synthesis of 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-3-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide (50)
  • Figure imgb0113
  • Starting material 49 (37 mg, 0.3 mmol) was dissolved in 2 ml dry DMF. Then EDCI (94 mg, 0.5 mmol) and HOBt (48 mg, 0.3 mmol) were added yielding a yellow solution into which 100 mg of starting material 20 (0.3 mmol) were added. Now the mixture was heated to 100 °C for 30 minutes. The reaction mixture was cooled to ambient temperature, mixed with water and the resulting precipitate was filtered and dried. This crude product was further purified by prep HPLC (Method 4) yielding the desired product 50 as light brown solid (53 mg, 0.1 mmol, 37 %).
    • General notes:
  • Analogously, p-chlorophenyl isocyanate was replaced by the following isocyanates:
    Figure imgb0114
  • Analogously, (4-chloro-2-fluoro-phenyl)-acetic acid (18) was replaced by the following acids:
    Figure imgb0115
  • Analogously, 1H-1,2,3-benzotiazole-5-carboxylic acid was replaced by the following acids:
    Figure imgb0116
  • Analogously, Pyridin-3-yl-acetic acid (49) was replaced by the following acids:
    Figure imgb0117
  • Analogously, pyridine-4-carbaldehyde (22) was replaced by the following aldehydes:
    Figure imgb0118
  • Analogously, 6-amino-3H-benzooxazol-2-one (30) was replaced by the following amines:
    Figure imgb0119
  • Analogously, 2-(4-Chloro-phenyl)-ethylamine (42) was replaced by the following amines:
    Figure imgb0120
    Figure imgb0121
    Figure imgb0122
    Figure imgb0123
    Figure imgb0124
  • An overview about further analogously synthesized compounds of the invention including physico-chemical parameters for all compounds of the invention is given in Tables 2 and 3. Table 2
    Compound Chemical Name ESI [M+1]+ HPLC Rt [min] HPLC Method LC-MS Method
    1 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 496 2,93 A B
    2 2-[3-(4-Chloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 512.1 2,95 (1,05) A (G) B (G)
    3 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-trifluoromethyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 530.2 2,99 (1,08) D (G) B (G)
    4 6-(1 H-Benzotriazole-5-carbonyl)-2-[3-(4-isopropyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 504 3,03 A B
    5 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-propionylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 509 2,91 A B
    6 2-[3-(4-Chloro-phenyl)-propionylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 525 3,03 A B
    7 2-[3-(4-Isopropyl-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 3,17 A B
    8 2-[3-(3,5-Dichloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 547 3,23 A B
    9 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluoro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 513 2,89 A B
    10 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 529 2,95 A B
    11 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(3-chloro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 495 2,81 A B
    12 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(3,5-dichloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 531 3,17 A B
    13 2-[2-(3-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 511 2,91 A B
    14 2-[2-(4-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 511.1 2,92 (1,01) A (G) B (G)
    15 6-(1 H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-2-fluoro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 514.1 2,87 (1,02) A (G) B (G)
    16 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-3-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 459 2,5 A B
    17 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 459 2,69 A B
    18 2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 442 2,73 A B
    19 2-[3-(4-Chloro-phenyl)-ureido]-6-(pyridine-3-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 456 2,83 A B
    20 2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 442 2,57 A B
    21 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 459 2,51 A B
    22 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-3-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 487 2,63 A B
    23 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-4-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 487 2,6 A B
    24 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(3-pyridin-2-yl-propionyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 501 2,57 A B
    25 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester 510,9 3,29 A B
    26 2-[3-(4-Chloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester 526,9 3,35 A B
    27 1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea 550 2,92 A B
    28 2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide] 505 3,28 A C
    29 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide 497 3,13 A C
    30 2-[3-(4-Trifluoromethyl-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide 480 3,23 A C
    31 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide 480 3,13 A C
    32 2-[3-(4-Trifluoromethyl-phenyl)-ureido]-benzothiazole-6-carboxylic acid (1H-benzotriazol-5-yl)-amide 498 3,2 A C
    33 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3,5-dichloro-benzylamide 470 not available F E
    34 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-benzylamide 436,2 not available F E
    35 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-propyl]-amide 464,2 3,65 F E
    36 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide 488,2 3,6 F E
    37 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide 484 4,5 F E
    38 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2,5-dichloro-benzylamide 470 3,52 F E
    39 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide 450,2 4,32 F E
    40 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-1-hydroxymethyl-ethyl]-amide 480,2 3,01 F E
    41 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-methoxy-benzylamide 432,2 2,99 F E
    42 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide 450,2 3,39 F E
    43 6-(1 H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-nitro-phenyl)-ethyl]-amide 461,1 3,12 F E
    44 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide 496,1 3,52 F E
    45 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 5-chloro-2-methoxy-benzylamide 466,1 3,41 F E
    46 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-2-fluoro-benzylamide 454,1 3,39 F E
    47 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide 434,2 3,23 F E
    48 [2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester 496 4,61 F E
    Table 3
    Compound Chemical Name ESI [M+1]+ HPLC Rt [min] Method F HPLC Rt [min] Method E
    49 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethylsulfanyl-benzylamide 502 3,82 2,10
    50 3-(1H-Benzotriazol-5-ylcarbamoyl)-1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethyl-benzyl ester 486 4,08 2,28
    51 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3-bromo-4-fluoro-benzylamide 498, 500 3,47 1,91
    52 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-dichloro-benzyl ester 487 4,07 2,22
    53 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzyl ester 554 4,23 2,36
    54 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethyl-benzyl ester 521 4,29 2,24
    55 3-(1 H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-trifluoromethyl-benzyl ester 486 4,03 2,21
    56 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethylsulfanyl-benzyl ester 518 4,35 2,27
    57 3-(1 H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethoxy-benzyl ester 502 4,16 2,28
    58 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethoxy-benzyl ester 537 4,37 2,29
    59 (1H-Benzotriazol-5-yl)-{3-[3-(4-methoxy-phenyl)-piperidine-1-carbonyl]-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl}-methanone 487 3,39 1,83
    60 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethoxy-benzylamide 486 3,60 2,04
    61 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide 470 3,52 2,01
    62 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amide 473 3,41 1,84
    63 3-{[6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carbonyl]-amino}-3-(4-tert-butyl-phenyl)-propionic acid methyl ester 531 4,00 2,19
  • In the following 1H-NMR data for selected compounds of the invention are displayed:
    • Compound 33, C21H17Cl2N7O2
      1H NMR (500 MHz, DMSO-d6) δ [ppm] = 13.15 (s, 1 H), 8.75 (s, 1 H), 8.03 (s, 1 H), 7.99 (d, J = 8.4, 1 H), 7.50 (d, J = 8.4, 1 H), 7.47 (s, 1 H), 7.34 (s, 2H), 4.79 (s, 2H), 4.40 (s, 2H), 4.12-3.65 (m, 2H), 2.95-2.60 (m, 3H).
    • Compound 37, C22H19Cl2N7O2
      1H NMR (500 MHz, DMSO-d6) δ [ppm] = 16.08 (s, 1 H), 13.22 - 12.55 (m, 1 H), 8.18 - 7.92 (m, 3H), 7.60 - 7.52 (m, 3H), 7.22 (d, J = 8.0, 1 H), 4.90 - 4.45 (m, 2H), 3.85 (s, 1 H), 3.60 - 3.40 (m, 3H), 2.84 (t, J = 12.3, 2H), 2.76 (s, 2H).
    • Compound 48, C24H19Cl2N5O3
      1H NMR (500 MHz, DMSO-d6) δ [ppm] = 9.76 (s, 1H), 8.05 - 7.87 (m, 2H), 7.58 (s, 1H), 7.49 (s, 3H), 7.35 - 7.12 (m, 3H), 5.15 (s, 2H), 4.82 - 4.40 (m, 2H), 4.02 - 3.50 (m, 2H), 2.84 (s, 2H), 2.35 - 2.20 (m, 1 H).
    • Compound 19, C21H18ClN5O3S
      1H NMR (500 MHz, DMSO) δ [ppm] = 10.86 (s, 1H), 10.20 (s, 1H), 8.71 (d, J = 4.5, 2H), 7.91 (s, 1 H), 7.52 (m, 3H), 7.35 (d, J = 8.1, 2H), 7.6 - 7.2 (br. s, 1H), 6.98 (br. s, 1H), 4.74 (s, 0.67 x 2H) and 4.56 (s, 0.33 x 2H), 3.90 (s, 0.33 x 2H) and 3.55 (s, 0.67 x 2H), 2.91 (s, 2H).
    • Compound 7, C26H25N5O5S
      1H NMR (500 MHz, DMSO) δ [ppm] = 11.86 (s, 1 H), 10.76 (s, 1 H), 9.95 (s, 1 H), 7.41 (s, 1 H), 7.39 (d, J = 8.3, 2H), 7.29 (d, J = 7.9, 1 H), 7.17 (m, 3H), 7.6 - 7.1 (br. s, 1H), 7.00 (br. s, 1H), 4.65 (s, 2H), 3.54 (m, 2H), 3.06 - 2.69 (m, 3H), 1.19 (d, J = 6.9, 6H).
    • Compound 29, C23H14ClFN4O4S
      1H NMR (400 MHz, DMSO) δ [ppm] = 12.83 (s, 1 H), 11.54 (s, 1 H), 10.33 (s, 1H), 8.59 (d, J = 1.7, 1H), 8.03 (dd, J = 8.5, 1.7, 1H), 7.86 (t, J = 8.5, 1H), 7.83 (d, J = 1.7, 1H), 7.54 - 7.41 (m, 3H), 7.30 (dd, J = 8.2, 1.9, 1H), 7.08 (d, J = 8.4, 1H), 3.97 (s, 2H).
    • Compound 31, C22H14CIN5O4S
      1H NMR (400 MHz, DMSO) δ [ppm] = 11.58 (s, 1H), 10.33 (s, 1H), 9.36 (s, 1 H), 8.53 (s, 1H), 8.03 - 7.94 (m, 1H), 7.84 (d, J = 1.9, 1H), 7.80 - 7.66 (m, 2H), 7.59 (m, 2H), 7.51 (dd, J = 8.5, 1.9, 1H), 7.44 - 7.36 (m, 2H), 7.09 (d, J = 8.4, 1 H).
    • 2-Amino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester hydrochloride (17), C9H12N2O2S*HCl
      1H NMR (400 MHz, DMSO) δ [ppm] = 7.35 (s, 2H), 4.59 (s, 2H), 3.77 (s, 2H), 3.68 (s, 3H), 3.04 (t, J = 5.9, 2H), 2.73 - 2.66 (m, 2H).
    • Compound 50
      1H NMR (500 MHz, DMSO) δ = 15.53 (s, 1H), 13.22 (s, 1H), 10.25 (s, 1H), 8.47 (s, 1H), 7.89 (s, 1H), 7.83-7.68 (m, 3H), 7.63 (d, J=8.0, 2H), 5.25 (s, 2H), 4.72-4.58 (m, 2H), 3.72 (s, 2H), 2.85 (s, 2H).
    • Compound 51
      1H NMR (500 MHz, DMSO) δ = 15.87 (s, 1 H), 13.10 (s, 1H), 8.69 (s, 1H), 8.07-7.90 (m, 2H), 7.61 (s, 1 H), 7.49 (d, J = 8.5, 1 H), 7.40-7.24 (m, 2H), 4.77 (s, 2H), 4.38 (s, 2H), 3.81 (s, 1 H), 3.53 (s, 1 H), 2.79 (s, 2H).
    • Compound 52
      1H NMR (500 MHz, DMSO, d-TFA exchanged, C21H14D3Cl2N7O3) δ = 8.48 (d, J=1.6, 1 H), 7.82 (d, J=9.0, 1H), 7.68 (dd, J = 9.0, 1.6, 1 H), 7.35-7.27 (m, 3H), 5.06 (s, 2H), 4.65-4.53 (m, 2H), 3.64 (s, 2H), 2.82 (t, J = 5.3, 2H).
    • Compound 53
      1H NMR (500 MHz, DMSO) δ = 15.54 (s, 1H), 13.22 (s, 1H), 10.24 (s, 1H), 8.46 (s, 1H), 8.13-8.07 (m, 3H), 7.89 (d, J = 7.9, 1H), 7.75 (s, 1H), 5.32 (s, 2H), 4.72-4.57 (m, 2H), 3.71 (s, 2H), 2.84 (s, 2H).
    • Compound 54
      1H NMR (500 MHz, DMSO) δ = 15.50 (s, 0H, 1H), 13.22 (s, 1H), 10.24 (s, 1H), 8.46 (s, 1H), 7.89 (d, J = 8.2, 2H), 7.79-7.70 (m, 2H), 7.58 (d, J=8.2, 1H), 5.24 (s, 2H), 4.75-4.60 (m, 2H), 3.79-3.63 (m, 2H), 2.86 (s, 2H).
    • Compound 55
      1H NMR (500 MHz, DMSO) δ = 15.50 (s, 1 H), 13.20 (s, 1 H), 10.22 (s, 1 H), 8.45 (s, 1H), 7.88 (d, J=7.9, 1H), 7.78-7.66 (m, 4H), 7.63 (t, J=7.7, 1H), 5.23 (s, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 2.83 (t, J=5.4, 2H).
    • Compound 58
      1H NMR (500 MHz, DMSO) δ = 15.54 (s, 1H), 13.22 (s, 1H), 10.25 (s, 1H), 8.47 (s, 1 H), 7.89 (s, 1 H), 7.80-7.73 (m, 2H), 7.60 (d, J=8.7, 1 H), 7.52 (dd, J=8.5, 1.9, 1H), 5.18 (s, 2H), 4.70-4-58 (m, 2H), 3.70 (s, 2H), 2.85 (s, 2H).
    • Compound 60
      1H NMR (500 MHz, DMSO) δ = 15.75 (s, 1H), 13.09 (s, 1H), 8.65 (s, 1H), 8.07 - 7.92 (m, 2H), 7.49 (d, J = 8.5, 1 H), 7.42 (d, J = 8.4, 2H), 7.30 (d, J = 8.2, 2H), 4.88-4.55 (m, 2H), 4.42 (d, J = 5.2, 2H), 3.99--3.45 (m, 2H), 2.80 (s, 2H).
  • The following analytical methods were use for determining above illustrated physico-chemical parameters:
    • ESI: Electrospray Ionization Mass Spectrometry (M+H)+
    Analytical chromatography methods

  • A HPLC-Method: 1_100_2 Speed (machine: LaChrom)
    • Column: Chromolith Performance RP18e 100-3mm
    • Flow: 2ml/min (Pump: L-7100)
    • Solvent A: water + 0.01% TFA
    • Solvent B: Acetonitrile + 0.01% TFA
    • Wavelength (WL): 220 nm (Detector: L-7455)
    • 0-0,2 100% A, 0,2 - 3,7 to 100% B, 3,7 - 4,4 100% B, 4,5 - 5,0 100% A

    B LC-MS-Method: polar.M (machine: Agilent 1100 Series)
    • Column: Chromolith Speed Rod RP18e-50-4.6
    • Flow: 2.4ml/min
    • Solvent A: water + 0,1 % TFA
    • Solvent B: Acetonitrile + 0,1% TFA
    • WL: 220 nm
    • Gradient: 0-2.6min: 4%B to 100%B, 2.6-3.3min:100%B

    C LC-MS-Method: polar.M (machine: Agilent 1100 Series)
    • Column: Chromolith Speed Rod RP18e-50-4.6
    • Flow: 2.4ml/min
    • Solvent A: water + 0,05% HCOOH
    • Solvent B: Acetonitrile + 0,04% HCOOH
    • WL: 220 nm
    • Gradient: 0-2.8min: 4%B to 100%B, 2.8-3.3min:100%B

    D HPLC-Method: 1_100_2 (machine: LaChrom)
    • Column: Chromolith Performance RP18e 100-3mm
    • Flow: 2ml/min (Pump: L-7100)
    • Solvent A: water + 0.01% HCOOH
    • Solvent B: Acetonitrile + 0.01% HCOOH
    • WL: 220 nm (Detector: L-7455)
    • 0-0,2 100% A, 0,2 - 3,7 to 100% B, 3,7 - 4,4 100% B, 4,5 - 5,0 100% A

    E HPLC/MS-Method (polar)
    Solvent A: water + 0,05 % HCOOH
    Solvent B: Acetonitrile + 0,04 % HCOOH
    Flow: 2,4 ml/min, WL : 220nm
    Gradient: 0,0 min 4 % B
    2,8 min 100 % B
    3,3 min 100% B

    3,4 min 4% B
    Column: Chromolith® Speed ROD RP-18e 50-4.6 mm
    F HPLC-Method (non-polar)
    • Solvent A: water + 0,1% TFA
    • Solvent B: Acetonitrile+ 0,08% TFA
    • Flow: 1,5 ml/min
    • Gradient: 0,0 min 20% B

    5,0 min 100% B
    5,5 min 100% B
    6,0 min 20% B
    6,5 min 20% B
    Column: Chromolith Performance RP18e 100-3
    G HPLC/MS-Method
    Machine: Waters Acquity UPLC® with PDA and ELSD; Waters SQD (ESI+/- and APCI +/-)
    Solvent A: Acetonitrile + 0,1 % HCOOH
    Solvent B: Water + 0,1 % HCOOH
    Flow: 1 ml/min, WL : 254nm
    Gradient: 0,0 min 1 % A
    1,7 min 99 % A
    2,0 min 99 % A

    Column: Acquity UPLC® BEH C18 (2.1 x 50mm)
    Column Temperature: 60 °C Preparative chromatography methods:
    • Prep.-HPLC-Method 1:
      • Machine: Agilent 1100 Series
      • Column: Chromolith Prep Rod RP18e
      • flow: 50ml/min
      • Solvent A: Acetonitrile + 0,1% TFA
      • Solvent B: water + 0,1% TFA
      • WL: 220 nm
      • Gradient: from 1 - 20% ACN in 2 min, from 20 - 40% ACN in 8 min, collect from 2 min to 11 min
    • Prep.-HPLC-Method 2:
      • Machine: Agilent 1100 Series
      • Column: Chromolith Prep Rod RP18e
      • Flow: 50ml/min
      • Solvent A: Acetonitrile + 0,1% TFA
      • Solvent B: Water + 0,1% TFA
      • WL: 220 nm
      • Gradient: from 1 - 30% ACN in 10 min, collect from 2 min to 11 min
    • Prep.-HPLC-Method 3:
      • machine: Agilent 1100 Series
      • Column: Chromolith Prep Rod RP18e
      • flow: 50ml/min
      • Solvent A: Acetonitrile + 0,1 % TFA
      • Solvent B: Water + 0,1% TFA
      • WL: 220 nm
      • Gradient: from 1 - 25% ACN in 2 min, from 25 - 50% ACN in 8 min, collect from 2 min to 11 min
    • Prep.-HPLC-Method 4:
      • Machine: Agilent 1100 Series
      • Column: Chromolith Prep Rod RP18e
      • flow: 50ml/min
      • Solvent A: Acetonitrile + 0,1% TFA
      • Solvent B: Water + 0,1% TFA
      • WL: 220 nm
      • Gradient: from 1 - 15 % ACN in 2 min, from 15 - 35 % ACN in 8 min, collect from 2 min to 11 min
    • Flashmaster Method 1:
      • Machine: Flashmaster
      • Column material: Chromolith NH2
      • solvent: ethyl acetate (EE)/MeOH
      • Gradient: 100%EE 5 min, in 15 min to 3% MeOH, in 16 min to 4% MeOH, in 15 min to 10%MeOH, 15 min MeOH flush
    II. Autotaxin Assay Assay Description
  • Autotaxin activity is measured indirectly by means of Amplex Red Reagent. In this course, Amplex Red is measured as fluorogenic indicator for generated H2O2. Autotaxin converts substrate lysophosphatidylcholine (LPC) to phosphocholine and lysophosphatidylic acid (LPA). After the conversion phosphocholine is reacted with alkaline phosphatase to obtain inorganic phosphate and choline. During the next step choline is oxidized with choline oxidase to yield betaine, whereby H2O2 is generated. H2O2 reacts with Amplex Red Reagent in the presence of peroxidase (Horseradish peroxidase) in an 1:1 stochiometry and yields highly fluorescent resorufin. The generated fluorescence is measured in a reaction-dependent kinetic mode in order to enable subtraction of fluorescence signals of possible other fluorescent compounds that are not part of the reaction from total measured fluorescence.
    • Performing the assay
  • 1,5 µl of a standard solution or of the compounds of the invention are dissolved in 20mM Hepes pH 7.2 with maximally 7.7% DMSO in individual concentrations. The resulting solution is pre-incubated together with 10 µl (16 ng) of highly purified recombinant autotaxin in a black 384-hole microtiter plate for 30 min at 22°C.
  • Thereafter, the reaction is started through the addition of 5µl L-a-lysophosphatidyl-choline (LPC), whereby the final concentration of LPC is 75 µM. The mixture is incubated for 90 min. at 37°C. After the incubation Amplex Red Reagent, peroxidase (Horseradish peroxidase) and choline oxidase are added. The fluorescence is immediately measured at a wavelength of 612 nm with an excitation wavelength of 485 nm in a "Tecan Ultra multimode" fluorescence reader. The activity of autotaxin is indirectly calculated via the amount of detected generated H2O2.
  • For IC50 analysis, ten serial 1:3 dilutions starting at 30 µM for each compound were run in duplicates.
  • IC50 values were calculated on normalized data. For normalization, control wells were added to each assay plate and the signal of uninhibited control wells was set to 100%, whereas the signal inhibited by 500µM C14 LPA, (Avanti Polar Lipids, Cat# 857120P) was set to 0%. Curves were fitted and IC50 values calculated by the following model using proprietory analysis software: Y = Bottom + 100 - Bottom / 1 + 10 ∧ ⁢ Log ⁢ IC 50 - X * HillSlope
    Figure imgb0125
    • Where X is the logarithm of concentration. Y is the response
    • ;Y starts at Bottom and goes to Top with a sigmoid shape.
    Material
    • Microtiter plate: PS-Microplate, 384-hole, small volume, black Corning, Cat#3677
    • Protein: Recombinant autotaxin (baculoviral Hi5 expression)
    • Substrate: L-a-lysophosphatidyl choline (chicken egg); Avanti Polar Lipids # 830071P
    • Standard: C14 LPA, Avanti Polar Lipids, Cat# 857120P
    • Detection Reagent: Amplex Red Reagent; Invitrogen # A12222; dissolved in 1.923 ml of DMSO peroxidase Type VI-A (horseradish), Sigma # P6782; dissolved in 7,45 ml of test buffer, Choline Oxidase ; Sigma # C5896; dissolved in 2,47 ml test buffer Detection Reagent Mix: 1:100 dilution of Amplex Red Regent in test buffer
    • Test buffer: 200 mM Tris-HCl, Merck, Cat # 1.08219, pH 7.9; 0.1 % BSA, lipid free, Roche Cat#775835
    Table 4
    Compound Chemical Name IC50 value [M] or %CTRL (1E-05)
    1 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-06
    2 2-[3-(4-Chloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-06
    3 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-trifluoromethyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    4 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-isopropyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    5 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-propionylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    6 2-[3-(4-Chloro-phenyl)-propionylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-06
    7 2-[3-(4-Isopropyl-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    8 2-[3-(3,5-Dichloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-05
    9 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluoro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    10 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxvlic acid amide < 1,00E-06
    11 6-(1H-Benzotriazole-5-carbonyl)-2-[2-(3-chloro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    12 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(3,5-dichloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-05
    13 2-[2-(3-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    14 2-[2-(4-Chloro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-06
    15 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-2-fluoro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-06
    16 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-3-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 3,00E-05
    17 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 66%
    18 2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide 88%
    19 2-[3-(4-Chloro-phenyl)-ureido]-6-(pyridine-3-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-05
    20 2-[3-(4-Chloro-phenyl)-ureido]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-05
    21 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-05
    22 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-3-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-05
    23 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylaminoJ-6-(2-pyridin-4-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1.00E-05
    24 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(3-pyridin-2-yl-propionyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide < 1,00E-05
    25 6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureidol-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester < 3,00E-05
    26 2-[3-(4-Chloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester < 1,00E-05
    27 1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea 52%
    28 2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide] < 3,00E-05
    29 2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide < 1,00E-05
    30 2-[3-(4-Trifluoromethyl-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide 93%
    31 2-[3-(4-Chloro-phenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide 94%
    32 2-[3-(4-Trifluoromethyl-phenyl)-ureido]-benzothiazole-6-carboxylic acid (1 H-benzotriazol-5-yl)-amide 64%
    33 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3,5-dichloro-benzylamide < 1.00E-05
    34 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-benzylamide < 1,00E-05
    35 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-propyl]-amide < 1,00E-05
    36 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide < 3.00E-05
    37 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide < 1,00E-05
    38 6-(1H-Benzotriazo)e-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2,5-dichloro-benzylamide < 1,00E-05
    39 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide < 1,00E-06
    40 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-1-hydroxymethyl-ethyl]-amide 73%
    41 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-methoxy-benzylamide 66%
    42 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide < 3,00E-05
    43 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-nitro-phenyl)-ethyl]-amide < 1,00E-05
    44 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-. amide < 1,00E-05
    45 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 5-chloro-2-methoxy-benzylamide < 1,00E-05
    46 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-2-fluoro-benzylamide 76%
    47 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide < 1,00E-05
    48 [2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester < 1,00E-05
    49 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethylsulfanyl-benzylamide < 3,00E-05
    50 3-(1H-Benzotriazol-5-ylcarbamoyl)-1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethyl-benzyl ester < 1,00E-06
    51 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3-bromo-4-fluoro-benzylamide < 1,00E-0
    52 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-dichloro-benzyl ester < 1,00E-06
    53 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzyl ester < 1,00E-06
    54 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethyl-benzyl ester < 1,00E-05
    55 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-trifluoromethyl-benzyl ester < 1,00E-06
    56 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethylsulfanyl-benzyl ester < 1,00E-06
    57 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethoxy-benzyl ester < 1,00E-05
    58 3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethoxy-benzyl ester < 1,00E-06
    59 (1H-Benzotriazol-5-yl)-{3-[3-(4-methoxy-phenyl)-piperidine-1-carbonyl]-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl}-methanone < 3,00E-05
    60 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethoxy-benzylamide < 3,00E-05
    61 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide < 1,00E-05
    62 6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amide < 1,00E-05
    63 3-{[6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carbonyl]-amino}-3-(4-tert-butyl-phenyl)-propionic acid methyl ester < 3,00E-05

Claims (15)

  1. Compound according to formula (I)
    Figure imgb0126
     wherein:
    W1, W2 together independently form "-N=N-, -C(O)-O-";
    Y1 is independently selected from the group consisting of "-C(O)-, - C(S)-, -N(R10)-C(O)-, -C(O)-N(R11)-, -C(R12)(R13)-, single bond";
    Y2 is independently selected from the group consisting of "-C(R14)(R15)-, -O-, -N(R16)-, -C(O)-NH-, single bond";
    Z1 is independently selected from the group consisting of "O, S, N(R17)";
    L is independently selected from the group consisting of the group consisting of:
    Figure imgb0127
    Figure imgb0128
    Figure imgb0129
    Figure imgb0130
    B is independently selected from the group consisting of "aryl", wherein "aryl" can be independently substituted with one or more identical or different substituents selected from the group consisting of: "(i) "hydrogen, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halogen, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, - NHX1, -NX2X3, -NO2, -OH, -OCF3, -SCF3, -SH, -O-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-X4, -C(O)O-X5, -C(O)NH-X6, -C(O)NX7X8, -O-X9, -O(-X10-O)a-H (a = 1, 2, 3, 4, 5), -O(-X11-O)b-X12 (b = 1, 2, 3, 4, 5), - OC(O)-X13, -OC(O)-O-X14, -OC(O)-NHX15, -O-C(O)-NX16X17, -OP(O)(OX18)(OX19), -OSi(X20)(X21)(X22), -OS(O2)-X23, - NHC(O)-NH2, -NHC(O)-X24, -NX25C(O)-X26, -NH-C(O)-O-X27, -NH-C(O)-NH-X28, -NH-C(O)-NX29X30, -NX31-C(O)-O-X32, - NX33-C(O)-NH-X34, -NX35-C(O)-NX36X37, -NHS(O2)-X38, - NX39S(O2)-X40, -S-X41, -S(O)-X42, -S(O2)-X43, -S(O2)NH-X44, -S(O2)NX45X46, -S(O2)O-X47, -P(O)(OX48)(OX49), - Si(X50)(X51)(X52), -C(NH)-NH2, -C(NX53)-NH2, -C(NH)-NHX54, -C(NH)-NX55X56, -C(NX57)-NHX58, -C(NX59)-NX60X61, -NH-C(O)-NH-O-X62, -NH-C(O)-NX63-O-X64, -NX65-C(O)-NX66-O-X67, -N(-C(O)-NH-O-X68)2, -N(-C(O)-NX69-O-X70)2, -N(-C(O)-NH-O-X71)(-C(O)-NX72-O-X73), -C(S)-X74, -C(S)-O-X75, -C(S)-NH-X76, -C(S)-NX77X78, -C(O)-NH-O-X79, -C(O)-NX80-O-X81, -C(S)-NH-O-X82, -C(S)-NX83-O-X84, -C(O)-NH-NH-X85, -C(O)-NH-NX86X87, -C(O)-NX88-NX89X90, - C(S)-NH-NH-X91, -C(S)-NH-NX92X93, -C(S)-NX94-NX95X96, - C(O)-C(O)-O-X97, -C(O)-C(O)-NH2, -C(O)-C(O)-NHX98, -C(O)-C(O)-NX99X100, -C(S)-C(O)-O-X101, -C(O)-C(S)-O-X102, - C(S)-C(S)-O-X103, -C(S)-C(O)-NH2, -C(S)-C(O)-NHX104, - C(S)-C(O)-NX105X106, -C(S)-C(S)-NH2, -C(S)-C(S)-NHX107, - C(S)-C(S)-NX108X109, -C(O)-C(S)-NH2, -C(O)-C(S)-NHX110, - C(O)-C(S)-NX111X112";
    wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49, X50, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102, X103, X104, X105, X106, X107, X108, X109, X110, X111, X112 are independently from each other selected from the group consisting of: "alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively X7, X8 and/or X16, X17 and/or X29, X30 and/or X36, X37 and/or X45, X46 and/or X55, X56 and/or X60, X61 and/or X77, X78 and/or X86, X87 and/or X89, X90 and/or X92, X93 and/or X95, X96 and/or X99, X100 and/or X105, X106 and/or X108, X109 and/or X111, X112 respectively together can also form "heterocyclyl";
    wherein optionally above substituents of substituents group (i) can in turn independently from each other be substituted with one or more identical or different substituents V;
    R1, R2, R3, R4, R10, R11, R12, R13, R14, R15, R16, R17 are independently from each other selected from the group consisting of: "V";
    V is independently selected from the group consisting of: "(i) "hydrogen, alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halogen, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, - NHA1, -NA2A3, -NO2, -OH, -OCF3, -SCF3, -SH, -O-SO3H, - OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, - C(O)-A4, -C(O)O-A5, -C(O)NH-A6, -C(O)NA7A8, -O-A9, -O(-A10-O)a-H (a = 1, 2, 3, 4, 5), -O(-A11-O)b-A12 (b = 1, 2, 3, 4, 5), - OC(O)-A13, -OC(O)-O-A14, -OC(O)-NHA15, -O-C(O)-NA16A17, -OP(O)(OA18)(OA19), -OSi(A20)(A21)(A22), -OS(O2)-A23, - NHC(O)-NH2, -NHC(O)-A24, -NA25C(O)-A26, -NH-C(O)-O-A27, -NH-C(O)-NH-A28, -NH-C(O)-NA29A30, -NA31-C(O)-O-A32, - NA33-C(O)-NH-A34, -NA35-C(O)-NA36A37, -NHS(O2)-A38, - NA39S(O2)-A40, -S-A41, -S(O)-A42, -S(O2)-A43, -S(O2)NH-A44, -S(O2)NA45A46, -S(O2)O-A47, -P(O)(OA48)(OA49), - Si(A50)(A51)(A52), -C(NH)-NH2, -C(NA53)-NH2, -C(NH)-NHA54, -C(NH)-NA55A56, -C(NA57)-NHA58, -C(NA59)-NA60A61, -NH-C(O)-NH-O-A62, -NH-C(O)-NA63-O-A64, -NA65-C(O)-NA66-O-A67, -N(-C(O)-NH-O-A68)2, -N(-C(O)-NA69-O-A70)2, -N(-C(O)-NH-O-A71)(-C(O)-NA72-O-A73), -C(S)-A74, -C(S)-O-A75, -C(S)-NH-A76, -C(S)-NA77A78, -C(O)-NH-O-A79, -C(O)-NA80-O-A81, -C(S)-NH-O-A82, -C(S)-NA83-O-A84, -C(O)-NH-NH-A85, -C(O)-NH-NA86A87, -C(O)-NA88-NA89A90, - C(S)-NH-NH-A91, -C(S)-NH-NA92A93, -C(S)-NA94-NA95A96, - C(O)-C(O)-O-A97, -C(O)-C(O)-NH2, -C(O)-C(O)-NHA98, -C(O)-C(O)-NA99A100, -C(S)-C(O)-O-A101, -C(O)-C(S)-O-A102, - C(S)-C(S)-O-A103, -C(S)-C(O)-NH2, -C(S)-C(O)-NHA104, - C(S)-C(O)-NA105A106, -C(S)-C(S)-NH2, -C(S)-C(S)-NHA107, - C(S)-C(S)-NA108A109, -C(O)-C(S)-NH2, -C(O)-C(S)-NHA110, - C(O)-C(S)-NA111A112";
    wherein A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104, A105, A106, A107, A108, A109, A110, A111, A112 are independently from each other selected from the group consisting of: "alkyl, (C9-C30)alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl; heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" and wherein alternatively A7, A8 and/or A16, A17 and/or A29, A30 and/or A36, A37 and/or A45, A46 and/or A55, A56 and/or A60, A61 and/or A77, A78 and/or A86, A87 and/or A89, A90 and/or A92, A93 and/or A95, A96 and/or A99, A100 and/or A105, A106 and/or A108, A109 and/or A111, A112 respectively together can also form "heterocyclyl";
    wherein optionally above substituents of substituents group (i) can in turn independently from each other be substituted with one or more identical or different substituents V;
    n is independently 0, 1, 2, 3 or 4;
    and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  2. The compound according to formula (I) as claimed in claim 1, wherein:
    Figure imgb0131
     is independently substituted for a chemical group selected from the group consisting of:
    Figure imgb0132
    Figure imgb0133
    Figure imgb0134
     and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  3. The compound according to formulae (I) as claimed in any of claims 1 to 2, wherein:
    W1, W2 together independently form "-N=N-, -C(O)-O-";
    Y1 is independently selected from the group consisting of "-C(O)-, - N(R10)-C(O)-, -C(O)-N(R11)-, -OC(O)-, single bond";
    Z1 is independently "O";
    B is independently selected from the group consisting of "4-chloro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethylsulfanyl-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro-4-trifluoromethoxy-phenyl, 3,5-bis-trifluoromethyl-phenyl, 4-isopropylphenyl, 4-tert.butyl-phenyl, 3,5-dichloro-phenyl, 4-chloro-2-fluoro-phenyl, 3-chloro-phenyl, 2-fluoro-5-trifluoromethyl-phenyl, 3-chloro-4-trifluoromethyl-phenyl, 3,4-dichloro-phenyl, 2,5-dichlorophenyl, 2-methoxy-phenyl, 4-methoxy-phenyl, 4-nitro-phenyl, 4-bromo-phenyl, 5-chloro-2-methoxy-phenyl, 4-fluoro-phenyl, 3-bromo-4-fluoro-phenyl, 6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl";
    R1, R2, R3, R4, R10, R11, R12, R13, R14, R15 are independently from each other selected from the group consisting of: "hydrogen, alkyl, methyl, isopropyl, tert.butyl, halogen, -F, -Br, -Cl, -CN, -CF3, -SF3, -OF3, - O-alkyl, -O-methyl, -NO2, -S(O)2-methyl"
    V is independently selected from the group consisting of "hydrogen, alkyl, methyl, isopropyl, tert.butyl, halogen, -F, -Br, -Cl, -CN, -CF3, -SF3, -OH, -O-alkyl, -O-methyl, -NO2, -S(O)2-methyl";
    n is independently 0, 1 or 2;
    and the physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
  4. A compound selected from the group consisting of: Compound 1
    Figure imgb0135
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 2
    Figure imgb0136
         2-[3-(4-Chlorophenyl)-ureido]-6-(2-oxo-2,3-dihydrobenzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 3
    Figure imgb0137
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-trifluoromethylphenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 4
    Figure imgb0138
         6-(1 H-Benzotriazole-5-carbonyl)-2-[3-(4-isopropyl-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 5
    Figure imgb0139
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-propionylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 6
    Figure imgb0140
         2-[3-(4-Chloro-phenyl)-propionylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 7
    Figure imgb0141
         2-[3-(4-Isopropylphenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 8
    Figure imgb0142
         2-[3-(3,5-Dichloro-phenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 9
    Figure imgb0143
         6-(1H-Benzotriazole-5-carbonyl)-2-[2-(4-chloro-2-fluorophenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 10
    Figure imgb0144
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 11
    Figure imgb0145
         6-(1H-Benzotriazole-5-carbonyl)-2-[2-(3-chloro-phenyl)-acetylamino]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 12
    Figure imgb0146
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(3,5-dichloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 13
    Figure imgb0147
         2-[2-(3-Chlorophenyl)-acetylamino]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 14
    Figure imgb0148
         2-[2-(4-Chlorophenyl)-acetylamino]-6-(2-oxo-2,3-dihydrobenzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 15
    Figure imgb0149
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-2-fluorophenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 16
    Figure imgb0150
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-3-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 17
    Figure imgb0151
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 18
    Figure imgb0152
         2-[3-(4-Chlorophenyl)-ureido]-6-pyridin-2-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 19
    Figure imgb0153
         2-[3-(4-Chloro-phenyl)-ureido]-6-(pyridine-3-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 20
    Figure imgb0154
         2-[3-(4-Chlorophenyl)-ureido]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 21
    Figure imgb0155
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-pyridin-4-ylmethyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 22
    Figure imgb0156
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-3-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 23
    Figure imgb0157
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(2-pyridin-4-yl-acetyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 24
    Figure imgb0158
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-6-(3-pyridin-2-yl-propionyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide     Compound 25
    Figure imgb0159
         6-(1H-Benzotriazole-5-carbonyl)-2-[3-(4-chloro-phenyl)-ureido]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester     Compound 26
    Figure imgb0160
         2-[3-(4-Chlorophenyl)-ureido]-6-(2-oxo-2,3-dihydro-benzooxazole-6-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid methyl ester     Compound 27
    Figure imgb0161
         1-[6-(1H-Benzotriazole-5-carbonyl)-3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl]-3-(4-chloro-phenyl)-urea     Compound 28
    Figure imgb0162
         2-[3-(4-Chloro-phenyl)-ureido]-1H-indole-3,6-dicarboxylic acid 3-amide 6-[(2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide]     Compound 29
    Figure imgb0163
         2-[2-(4-Chloro-2-fluoro-phenyl)-acetylamino]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide     Compound 30
    Figure imgb0164
         2-[3-(4-Trifluoromethylphenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide     Compound 31
    Figure imgb0165
         2-[3-(4-Chlorophenyl)-ureido]-benzothiazole-6-carboxylic acid (2-oxo-2,3-dihydro-benzooxazol-6-yl)-amide     Compound 32
    Figure imgb0166
         2-[3-(4-Trifluoromethylphenyl)-ureido]-benzothiazole-6-carboxylic acid (1H-benzotriazol-5-yl)-amide     Compound 33
    Figure imgb0167
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3,5-dichloro-benzylamide     Compound 34
    Figure imgb0168
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-benzylamide     Compound 35
    Figure imgb0169
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-propyl]-amide     Compound 36
    Figure imgb0170
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-fluoro-5-trifluoromethyl-     benzylamide Compound 37
    Figure imgb0171
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide     Compound 38
    Figure imgb0172
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2,5-dichloro-benzylamide     Compound 39
    Figure imgb0173
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide     Compound 40
    Figure imgb0174
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-chloro-phenyl)-1-hydroxymethyl-ethyl]-amide     Compound 41
    Figure imgb0175
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 2-methoxy-benzylamide     Compound 42
    Figure imgb0176
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide     Compound 43
    Figure imgb0177
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-nitro-phenyl)-ethyl]-amide     Compound 44
    Figure imgb0178
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide     Compound 45
    Figure imgb0179
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 5-chloro-2-methoxy-benzylamide     Compound 46
    Figure imgb0180
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-chloro-2-fluorobenzylamide     Compound 47
    Figure imgb0181
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide     Compound 48
    Figure imgb0182
         [2-(1H-Benzotriazole-5-carbonyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-carbamic acid 3,5-dichloro-benzyl ester     Compound 49
    Figure imgb0183
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethylsulfanyl -benzylamide     Compound 50
    Figure imgb0184
         3-(1H-Benzotriazol-5-ylcarbamoyl)-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethyl-benzyl ester     Compound 51
    Figure imgb0185
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 3-bromo-4-fluorobenzylamide     Compound 52
    Figure imgb0186
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-dichloro-benzyl ester     Compound 53
    Figure imgb0187
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 3,5-bis-trifluoromethyl-benzyl ester     Compound 54
    Figure imgb0188
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethyl-benzyl ester     Compound 55
    Figure imgb0189
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 3-trifluoromethyl-benzyl ester     Compound 56
    Figure imgb0190
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethylsulfanyl -benzyl ester     Compound 57
    Figure imgb0191
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 4-trifluoromethoxy-benzyl ester     Compound 58
    Figure imgb0192
         3-(1H-Benzotriazol-5-ylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 3-chloro-4-trifluoromethoxy-benzyl ester     Compound 59
    Figure imgb0193
         (1H-Benzotriazol-5-yl)-{3-[3-(4-methoxyphenyl)-piperidine-1-carbonyl]-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl}-methanone     Compound 60
    Figure imgb0194
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethoxybenzylamide     Compound 61
    Figure imgb0195
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 4-trifluoromethyl-benzylamide     Compound 62
    Figure imgb0196
         6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amide     Compound 63
    Figure imgb0197
         3-{[6-(1H-Benzotriazole-5-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carbonyl]-amino}-3-(4-tert-butyl-phenyl)-propionic acid methyl ester
  5. Process for the preparation of a compound according to formula (I) as claimed in any of claims 1 to 4 comprising the steps:
    (a) reacting a compound of the formula (II),
    Figure imgb0198
     wherein W1, W2, R1, R2 have the meanings as indicated in claim 1, with a compound of the formula (III)
    Figure imgb0199
     wherein L is selected from the group consisting of:
    Figure imgb0200
    Figure imgb0201
    Figure imgb0202
    Figure imgb0203
     and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claim 1, in which Y1 denotes "-C(O)-";
    or
    (b) reacting a compound of the formula (II)
    Figure imgb0204
     wherein W1, W2, R1, R2 have the meanings as indicated in claim 1, with a compound L selected from the group consisting of:
    Figure imgb0205
    Figure imgb0206
     to yield a compound of the formula (IIa)
    Figure imgb0207
     wherein W1, W2. R1, R2 have the meanings as indicated in claim 1; further reacting the compound of formula (IIa) with a compound of formula (IV)
    Figure imgb0208
     wherein R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claim 1, in which Z1 denotes "O" and Y2 denotes "-N(R16)-" and R16 denotes "H";
    or
    (c) reacting a compound of the formula (Va) or (Vb)
    Figure imgb0209
     wherein m and n independently are 0, 1 or 2, with a compound of the formula (III)
    Figure imgb0210
     wherein L is selected from the group consisting of:
    Figure imgb0211
    Figure imgb0212
    Figure imgb0213
    Figure imgb0214
     and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claims 1 and 2, in which Y1 denotes "-C(R12)(R13)- and R12, R13 both denote "H" or Y1 denotes "-C(O)-",
    or
    (d) reacting a compound of the formula (VI)

            HO(O)C-L     (VI)

    wherein L is selected from the group consisting of:
    Figure imgb0215
    Figure imgb0216
     with a compound of the formula (VII)
    Figure imgb0217
     wherein W1, W2. R1, R2 have the meanings as indicated in claim 1; to yield a compound of the formula (VIII)
    Figure imgb0218
     wherein W1, W2, R1, R2 have the meanings as indicated in claim 1; further reacting the compound of formula (VIII) with a compound of formula (IV)
    Figure imgb0219
     wherein R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claim 1, in which Y1 denotes "-N(R10)-C(O)-", R10 denotes "H", Z1 denotes "O", Y2 denotes "-N(R16)-" and R16 denotes "H";
    or
    (e) reacting a compound of the formula (IX)
    Figure imgb0220
     wherein L is selected from the group consisting of:
    Figure imgb0221
    Figure imgb0222
     and wherein Z1, Y2, R3, R4, B, n have the meanings as indicated in claim 1, with a compound of the formula (VII)
    Figure imgb0223
     wherein W1, W2, R1, R2 have the meanings as indicated in claim 1; to yield a compound according to formula (I) as indicated in claim 1, in which Y1 denotes "-N(R10)-C(O)-" and R10 denotes "H".
    or
    (f) reacting a compound of the formula (X)
    Figure imgb0224
     wherein W1, W2, R1, R2, Y1 have the meanings as indicated in claim 1, wherein L is selected from the group consisting of:
    Figure imgb0225
     with a compound of formula (XI)
    Figure imgb0226
     wherein R3, R4, B, n have the meanings as indicated in claim 1, to yield a compound according to formula (I) as indicated in claim 1, in which Z1 denotes "O", Y2 denotes "-N(R16)-" and R16 denotes "H".
  6. Medicament comprising at least one compound as claimed in any of claims 1 to 4.
  7. Medicament comprising at least one compound as claimed in any of claims 1 to 4 for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin.
  8. Medicament comprising at least one compound as claimed in any of claims 1 to 4 for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions selected from the group consisting of: "cancer, tumour, malignant tumours, benign tumours, solid tumours, sarcomas, carcinomas, hyperproliferative disorders, carcinoids, Ewing sarcomas, Kaposi sarcomas, brain tumours, tumours originating from the brain and/or the nervous system and/or the meninges, gliomas, glioblastomas, neuroblastomas, stomach cancer, kidney cancer, kidney cell carcinomas, prostate cancer, prostate carcinomas, connective tissue tumours, soft tissue sarcomas, pancreas tumours, liver tumours, head tumours, neck tumours, laryngeal cancer, oesophageal cancer, thyroid cancer, osteosarcomas, retinoblastomas, thymoma, testicular cancer, lung cancer, lung adenocarcinoma, small cell lung carcinoma, bronchial carcinomas, breast cancer, mamma carcinomas, intestinal cancer, colorectal tumours, colon carcinomas, rectum carcinomas, gynaecological tumours, ovary tumours/ovarian tumours, uterine cancer, cervical cancer, cervix carcinomas, cancer of body of uterus, corpus carcinomas, endometrial carcinomas, urinary bladder cancer, urogenital tract cancer, bladder cancer, skin cancer, epithelial tumours, squamous epithelial carcinoma, basaliomas, spinaliomas, melanomas, intraocular melanomas, leukaemias, monocyte leukaemia, chronic leukaemias, chronic myelotic leukaemia, chronic lymphatic leukemia, acute leukaemias, acute myelotic leukaemia, acute lymphatic leukemia, lymphomas, angiogenesis, arteriosclerosis, opthalmic diseases, choroidal neovascularization, diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing and/or transplant rejection".
  9. The medicament as claimed in claim 6, wherein in such medicament comprises at least one additional pharmacologically active substance.
  10. The medicament as claimed in any of claims 7 and 8 for use wherein in such medicament comprises at least one additional pharmacologically active substance.
  11. The medicament as claimed in claim 6, wherein the medicament is applied before and/or during and/or after treatment with at least one additional pharmacologically active substance.
  12. The medicament as claimed in any of claims 7 to 8 for use, wherein the medicament is applied before and/or during and/or after treatment with at least one additional pharmacologically active substance.
  13. Pharmaceutical composition comprising a therapeutically effective amount of at least one compound as claimed in any of claims 1 to 4.
  14. The pharmaceutical composition as claimed in claim 13 further comprising at least one additional compound selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, diluents, carriers and/or additional pharmaceutically active substance other than the compound as claimed in any of claims 1 to 4.
  15. Kit comprising a therapeutically effective amount of at least one compound as claimed in any of claims 1 to 4 and/or at least one pharmaceutical composition as claimed in any of claims 13 to 14 and a therapeutically effective amount of at least one further pharmacologically active substance other than the compound as claimed in any of claims 1 to 4.
EP10707839.6A 2009-04-02 2010-03-09 Autotaxin inhibitors Not-in-force EP2414346B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10707839.6A EP2414346B1 (en) 2009-04-02 2010-03-09 Autotaxin inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09004866 2009-04-02
EP10707839.6A EP2414346B1 (en) 2009-04-02 2010-03-09 Autotaxin inhibitors
PCT/EP2010/001457 WO2010112124A1 (en) 2009-04-02 2010-03-09 Autotaxin inhibitors

Publications (2)

Publication Number Publication Date
EP2414346A1 EP2414346A1 (en) 2012-02-08
EP2414346B1 true EP2414346B1 (en) 2015-06-24

Family

ID=42235629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10707839.6A Not-in-force EP2414346B1 (en) 2009-04-02 2010-03-09 Autotaxin inhibitors

Country Status (14)

Country Link
US (2) US8329907B2 (en)
EP (1) EP2414346B1 (en)
JP (1) JP5779172B2 (en)
KR (1) KR20120004483A (en)
CN (1) CN102369195B (en)
AR (1) AR076007A1 (en)
AU (1) AU2010230585B2 (en)
CA (1) CA2757415C (en)
EA (1) EA201101396A1 (en)
ES (1) ES2547124T3 (en)
IL (1) IL215259A (en)
MX (1) MX2011010218A (en)
SG (1) SG174518A1 (en)
WO (1) WO2010112124A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
CN102358742B (en) * 2011-08-24 2014-04-09 天津药物研究院 Thiazole compound with antitumor activity
EA201492223A1 (en) 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг NEW DIAZASPYROCYCLO ALKANES AND AZASPIROCYCLO ALKANES
CN102702135B (en) * 2012-06-15 2014-05-28 中国农业大学 Benzoyl thiourea compound with benzothiazole structure and preparation method and application of compound
EP2900669B1 (en) 2012-09-25 2019-09-04 F.Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
JP6363616B2 (en) 2012-12-19 2018-07-25 ノバルティス アーゲー Autotaxin inhibitor
WO2014133112A1 (en) * 2013-03-01 2014-09-04 国立大学法人東京大学 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
AR095079A1 (en) * 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
ES2824723T3 (en) 2013-03-14 2021-05-13 Galapagos Nv New compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015042052A1 (en) * 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
CA2930737C (en) 2013-11-22 2023-02-21 Pharmakea, Inc. Autotaxin inhibitor compounds
KR20160088878A (en) 2013-11-22 2016-07-26 파마케아, 인크. Tetracyclic autotaxin inhibitors
KR20160087900A (en) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 New octahydro-cyclobuta [1,2-c ; 3,4-c']dipyrrol-2-yl
UA119347C2 (en) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (en) * 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 Bicyclic compound as autocrine motility factor (ATX) and lysophosphatidic acid (LPA) production inhibitor
PE20170206A1 (en) 2014-04-04 2017-04-09 X-Rx Inc SPIROCYCLIC INHIBITORS SUBSTITUTE FOR AUTOTAXIN
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
KR20240060887A (en) 2015-05-27 2024-05-08 사브레 테라퓨틱스 엘엘씨 Autotaxin inhibitors and uses thereof
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MX2018001430A (en) 2015-09-24 2018-04-20 Hoffmann La Roche New bicyclic compounds as dual atx/ca inhibitors.
KR20180053408A (en) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 A novel biocompatible compound as an autoantix (ATX) / carbonic anhydrase (CA) inhibitor
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
EP3182211A1 (en) * 2015-12-17 2017-06-21 Nivarox-FAR S.A. Composite part with resilient means under stress
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN110382484B (en) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 Novel bicyclic compounds as ATX inhibitors
RU2019132254A (en) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг HETEROCYCLIC COMPOUNDS SUITABLE AS DUAL ATX / CA INHIBITORS
KR102526964B1 (en) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Substituted pyrrolizine compounds as HBV replication inhibitors
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
CN112778274B (en) * 2019-11-05 2022-02-15 四川海思科制药有限公司 Nitrogen-containing heterocyclic derivative and preparation thereof
CN111454278B (en) * 2020-05-15 2021-03-19 四川大学 PAK1 inhibitor, synthesis thereof and application thereof in preparation of antitumor drugs
CN117980300A (en) * 2021-09-21 2024-05-03 明斯特大学 Autotaxin inhibitors
KR102502940B1 (en) * 2021-11-30 2023-02-24 주식회사 넥스트젠바이오사이언스 Novel compounds as autotaxin inhibitors and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102101A3 (en) 1997-11-10 2002-11-28 Bristol Myers Squibb Co Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
DE19834751A1 (en) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituted bicyclic heterocycles, their preparation and their use as medicines
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp Use of anti-vegf antibody to enhance radiation in cancer therapy
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US20030139431A1 (en) 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
JP2006525366A (en) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Heterocyclic carboxylic acid substituent
CN1984660B (en) 2003-07-03 2010-12-15 美瑞德生物工程公司 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
CA2559733C (en) * 2004-03-26 2014-05-13 Methylgene Inc. Inhibitors of histone deacetylase
ATE405553T1 (en) 2004-12-08 2008-09-15 Bristol Myers Squibb Co HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
CA2587664A1 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
NZ555737A (en) 2005-01-07 2010-01-29 Pfizer Prod Inc Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
BRPI0608581A2 (en) 2005-03-14 2010-01-19 Transtech Pharma Inc Benzazole derivatives, compositions and methods of use as b-secretase inhibitors
AU2006232109A1 (en) 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2009545531A (en) 2006-07-24 2009-12-24 ユニバーシティ オブ バージニア パテント ファンデーション Phosphonate vinyl lysophosphatidic acid receptor antagonist
GB0619176D0 (en) 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
WO2008060621A2 (en) 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
PL2121660T3 (en) 2007-01-25 2015-06-30 Du Pont Fungicidal amides
WO2008124393A1 (en) * 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
US8497283B2 (en) 2013-07-30
US20120015976A1 (en) 2012-01-19
CN102369195A (en) 2012-03-07
KR20120004483A (en) 2012-01-12
WO2010112124A1 (en) 2010-10-07
EA201101396A1 (en) 2012-09-28
SG174518A1 (en) 2011-10-28
US20130023556A1 (en) 2013-01-24
CA2757415C (en) 2018-02-06
AU2010230585B2 (en) 2016-03-24
JP2012522734A (en) 2012-09-27
US8329907B2 (en) 2012-12-11
CN102369195B (en) 2014-04-16
CA2757415A1 (en) 2010-10-07
IL215259A (en) 2016-05-31
AR076007A1 (en) 2011-05-11
ES2547124T3 (en) 2015-10-01
EP2414346A1 (en) 2012-02-08
JP5779172B2 (en) 2015-09-16
IL215259A0 (en) 2011-12-29
MX2011010218A (en) 2011-10-10
AU2010230585A1 (en) 2011-11-17
AU2010230585A8 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
EP2414346B1 (en) Autotaxin inhibitors
EP2626072B1 (en) Piperidine and piperazine derivatives as autotaxin inhibitors
EP2352732B1 (en) 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
ES2429843T3 (en) Piperidine and piperazine derivatives for the treatment of tumors
US8710058B2 (en) Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
EP2193122B1 (en) Imidazole derivatives
US20110257180A1 (en) Novel Polymorphic Forms of 6-(1-methyl-1H-pyrazol-4-yl)-2--2H-pyridazin-3-one Dihydrogenphosphate and Processes of Manufacturing thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150121

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 732830

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010025408

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2547124

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20151001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150924

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 732830

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150624

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150924

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150925

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150624

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151026

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151024

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010025408

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160309

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100309

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160331

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200225

Year of fee payment: 11

Ref country code: GB

Payment date: 20200226

Year of fee payment: 11

Ref country code: IT

Payment date: 20200221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200313

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200214

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200401

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010025408

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211001

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210309

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210309

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210310